1: Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE,
Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M 3rd, Hope TA, Carroll PR,
Feng FY. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal
Disease in Prostate Cancer. Eur Urol Oncol. 2019 Jan 14. pii:
S2588-9311(18)30194-9. doi: 10.1016/j.euo.2018.11.002. [Epub ahead of print]
PubMed PMID: 31411984.


2: Mansbridge M, Chung E, Rhee H. The Use of MRI and PET Imaging Studies for
Prostate Cancer Management: Brief Update, Clinical Recommendations, and
Technological Limitations. Med Sci (Basel). 2019 Aug 5;7(8). pii: E85. doi:
10.3390/medsci7080085. Review. PubMed PMID: 31387208.


3: Raveenthiran S, Yaxley J, Gianduzzo T, Kua B, McEwan L, Wong D, Tsang G,
MacKean J. The use of (68)Ga-PET/CT PSMA to determine patterns of disease for
biochemically recurrent prostate cancer following primary radiotherapy. Prostate 
Cancer Prostatic Dis. 2019 Sep;22(3):385-390. doi: 10.1038/s41391-019-0163-0.
Epub 2019 Jul 30. PubMed PMID: 31363165.


4: Klingenberg S, Jochumsen MR, Pedersen BG, Bouchelouche K. 68Ga-PSMA Uptake in 
Escherichia coli Spondylodiscitis. Clin Nucl Med. 2019 Jul 29. doi:
10.1097/RLU.0000000000002752. [Epub ahead of print] PubMed PMID: 31361648.


5: Seniaray N, Verma R, Belho E, Malik D, Mahajan H. Diffuse Pulmonary Metastases
From Prostate Cancer on 68Ga PSMA PET/CT. Clin Nucl Med. 2019 Jul 29. doi:
10.1097/RLU.0000000000002753. [Epub ahead of print] PubMed PMID: 31361647.


6: Dhiantravan N, Hovey E, Bosco A, Wegner EA. Concomitant Prostate Carcinoma and
Follicular Lymphoma: "Flip-Flop" Appearances on PSMA and FDG PET/CT Scans. Clin
Nucl Med. 2019 Jul 24. doi: 10.1097/RLU.0000000000002727. [Epub ahead of print]
PubMed PMID: 31348079.


7: Davidson T, Amit U, Saad A, Hahiashvili M, Goshen E, Portnoy O, Berger R,
Goldstein A, Sadetsky I, Weizman N, Chikman B, Dotan Z, Lawrence YR, Ben-Haim S, 
Symon Z, Goldstein J. Gallium-68 prostate-specific membrane antigen PET-CT and
the clinical management of prostate cancer. Nucl Med Commun. 2019
Sep;40(9):913-919. doi: 10.1097/MNM.0000000000001047. PubMed PMID: 31343612.


8: Meißner S, Janssen JC, Prasad V, Diederichs G, Hamm B, Brenner W, Makowski MR.
Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging:
Comparison to (68)Ga-PSMA PET-CT. Sci Rep. 2019 Jul 24;9(1):10727. doi:
10.1038/s41598-019-46386-3. PubMed PMID: 31341209; PubMed Central PMCID:
PMC6656738.


9: Frigerio B, Morlino S, Luison E, Seregni E, Lorenzoni A, Satta A, Valdagni R, 
Bogni A, Chiesa C, Mira M, Canevari S, Alessi A, Figini M. Anti-PSMA
(124)I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of
principle. J Exp Clin Cancer Res. 2019 Jul 23;38(1):326. doi:
10.1186/s13046-019-1325-6. PubMed PMID: 31337429; PubMed Central PMCID:
PMC6651934.


10: Raveenthiran S, Esler R, Yaxley J, Kyle S. The use of (68)Ga-PET/CT PSMA in
the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl
Med Mol Imaging. 2019 Jul 23. doi: 10.1007/s00259-019-04432-2. [Epub ahead of
print] PubMed PMID: 31332498.


11: Hanske J, Ostholt J, Roghmann F, Müller G, Braun K, Gomez B, von Landenberg
N, von Bodman C, Palisaar RJ, Liermann D, Noldus J, Brock M. Salvage lymph node
dissection in hormone-naïve men: How effective is surgery? Urol Oncol. 2019 Jul
18. pii: S1078-1439(19)30252-2. doi: 10.1016/j.urolonc.2019.06.023. [Epub ahead
of print] PubMed PMID: 31327750.


12: Acksteiner C, Sounness B. Incidental Finding of Acute Lymphocytic Leukemia in
a Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med. 2019
Sep;44(9):e529-e531. doi: 10.1097/RLU.0000000000002712. PubMed PMID: 31306192.


13: Koerber SA, Stach G, Kratochwil C, Haefner MF, Rathke H, Herfarth K, Kopka K,
Holland-Letz T, Choyke PL, Will L, Haberkorn U, Debus J, Giesel FL. Lymph node
involvement in treatment-naïve prostate cancer patients - correlation of
PSMA-PET/CT imaging and Roach formula in 280 men in the Radiotherapeutic
management. J Nucl Med. 2019 Jul 13. pii: jnumed.119.227637. doi:
10.2967/jnumed.119.227637. [Epub ahead of print] PubMed PMID: 31302638.


14: Onal C, Torun N, Akyol F, Guler OC, Hurmuz P, Yildirim BA, Cağlar M, Reyhan
M, Ozyigit G. Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for
Prostate Cancer Patients. Clin Nucl Med. 2019 Sep;44(9):e510-e516. doi:
10.1097/RLU.0000000000002691. PubMed PMID: 31283600.


15: Morsing A, Hildebrandt MG, Vilstrup MH, Wallenius SE, Gerke O, Petersen H,
Johansen A, Andersen TL, Høilund-Carlsen PF. Hybrid PET/MRI in major cancers: a
scoping review. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2138-2151. doi:
10.1007/s00259-019-04402-8. Epub 2019 Jul 2. PubMed PMID: 31267161.


16: Kalapara AA, Nzenza T, Pan HY, Ballok Z, Ramdave S, O'Sullivan R, Ryan A,
Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP,
Frydenberg M. Detection and localisation of primary prostate cancer using (68)
Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens. BJU Int. 
2019 Jul 1. doi: 10.1111/bju.14858. [Epub ahead of print] PubMed PMID: 31260602.


17: Schollhammer R, de Clermont Gallerande H, Robert G, Yacoub M, Vimont D,
Hindié E, Fernandez P, Morgat C. 68Ga-PSMA-617 Compared With 68Ga-RM2 and
18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer. Clin
Nucl Med. 2019 Sep;44(9):e535-e536. doi: 10.1097/RLU.0000000000002672. PubMed
PMID: 31246685.


18: Mena E, Lindenberg LM, Choyke PL. New Targets for PET Molecular Imaging of
Prostate Cancer. Semin Nucl Med. 2019 Jul;49(4):326-336. doi:
10.1053/j.semnuclmed.2019.02.001. Epub 2019 Mar 9. Review. PubMed PMID: 31227055.


19: Farolfi A, Lima GM, Oyen W, Fanti S. Molecular Imaging and Theranostics-A
Multidisciplinary Approach. Semin Nucl Med. 2019 Jul;49(4):247-254. doi:
10.1053/j.semnuclmed.2019.02.002. Epub 2019 Mar 2. Review. PubMed PMID: 31227048.


20: Meyer AR, Rowe SP, Gorin MA. Preoperative PSMA-targeted PET imaging: more
than just a tool for prostate cancer staging? BJU Int. 2019 Jul;124(1):2-3. doi: 
10.1111/bju.14624. PubMed PMID: 31207000.


21: Petersen LJ, Nielsen JB, Langkilde NC, Petersen A, Afshar-Oromieh A, De Souza
NM, De Paepe K, Fisker RV, Arp DT, Carl J, Haberkorn U, Zacho HD. (68)Ga-PSMA
PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node
staging prior to definitive radiotherapy in prostate cancer: a prospective
diagnostic test accuracy study. World J Urol. 2019 Jun 12. doi:
10.1007/s00345-019-02846-z. [Epub ahead of print] PubMed PMID: 31190153.


22: Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L,
Holt T, Hruby G, Pryor D, Sidhom M, Skala M, Yaxley J, Shakespeare TP.
Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the
Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother
Oncol. 2019 Jun 6;140:68-75. doi: 10.1016/j.radonc.2019.05.016. [Epub ahead of
print] PubMed PMID: 31177044.


23: Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, Guminski A, Eade
T. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected
via Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol
Oncol. 2018 Dec;1(6):531-537. doi: 10.1016/j.euo.2018.04.017. Epub 2018 May 23.
PubMed PMID: 31158100.


24: Kimura S, Abufaraj M, Janisch F, Iwata T, Parizi MK, Foerster B, Fossati N,
Briganti A, Egawa S, Hartenbach M, Shariat SF. Performance of [(68)Ga] Ga-PSMA 11
PET for detecting prostate cancer in the lymph nodes before salvage lymph node
dissection: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis.
2019 May 30. doi: 10.1038/s41391-019-0156-z. [Epub ahead of print] PubMed PMID:
31147628.


25: Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, 
Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D. Risk of metastatic disease on
(68) gallium-prostate-specific membrane antigen positron emission
tomography/computed tomography scan for primary staging of 1253 men at the
diagnosis of prostate cancer. BJU Int. 2019 May 29. doi: 10.1111/bju.14828. [Epub
ahead of print] PubMed PMID: 31141284.


26: Esen T, Kılıç M, Seymen H, Acar Ö, Demirkol MO. Can Ga-68 PSMA PET/CT replace
conventional imaging modalities for primary lymph node and bone staging of
prostate cancer? Eur Urol Focus. 2019 May 18. pii: S2405-4569(19)30142-7. doi:
10.1016/j.euf.2019.05.005. [Epub ahead of print] Review. PubMed PMID: 31113757.


27: Ganeshalingam R, Hsiao E. Compressed Central Zone Uptake on PSMA PET/CT-A
Potential Pitfall in Interpretation. Clin Nucl Med. 2019 Jul;44(7):570-571. doi: 
10.1097/RLU.0000000000002608. PubMed PMID: 31107744.


28: van Leeuwen FWB, van Oosterom MN, Meershoek P, van Leeuwen PJ, Berliner C,
van der Poel HG, Graefen M, Maurer T. Minimal-Invasive Robot-Assisted
Image-Guided Resection of Prostate-Specific Membrane Antigen-Positive Lymph Nodes
in Recurrent Prostate Cancer. Clin Nucl Med. 2019 Jul;44(7):580-581. doi:
10.1097/RLU.0000000000002600. PubMed PMID: 31107740.


29: Caglic I, Kovac V, Barrett T. Multiparametric MRI - local staging of prostate
cancer and beyond. Radiol Oncol. 2019 May 8;53(2):159-170. doi:
10.2478/raon-2019-0021. PubMed PMID: 31103999; PubMed Central PMCID: PMC6572496.


30: De Bari B, Mazzola R, Aiello D, Aloi D, Gatta R, Corradini S, Salgarello M,
Alongi F. ((68)Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer
recurrence: Possible implications on treatment volumes for radiation therapy.
Cancer Radiother. 2019 Jun;23(3):194-200. doi: 10.1016/j.canrad.2018.09.003. Epub
2019 May 12. PubMed PMID: 31088725.


31: Wu H, Xu T, Wang X, Yu YB, Fan ZY, Li DX, Luo L, Yang XC, Jiao W, Niu HT.
Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen
Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging
for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical
Prostatectomy: A Systematic Review and Meta-analysis. World J Mens Health. 2019
Apr 3. doi: 10.5534/wjmh.180124. [Epub ahead of print] PubMed PMID: 31081294.


32: Wondergem M, van der Zant F, Broos W, Knol R. Increased PSMA Expression in
Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of
Enzalutamide Indicated by 18F-DCFPyL PET/CT. Clin Nucl Med. 2019
Jul;44(7):582-584. doi: 10.1097/RLU.0000000000002585. PubMed PMID: 31058686.


33: Piron S, De Man K, Van Laeken N, D'Asseler Y, Bacher K, Kersemans K, Ost P,
Decaestecker K, Deseyne P, Fonteyne V, Lumen N, Achten E, Brans B, De Vos F.
Radiation dosimetry and biodistribution of (18)F-PSMA-11 for PET imaging of
prostate cancer. J Nucl Med. 2019 Apr 26. pii: jnumed.118.225250. doi:
10.2967/jnumed.118.225250. [Epub ahead of print] PubMed PMID: 31028165.


34: Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergul N, Sahin S, Tugcu V, Inci
E, Tasci AI, Cermik TF. Comparison of preoperative locoregional Ga-68 PSMA-11
PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
Prostate. 2019 Jun;79(9):1007-1017. doi: 10.1002/pros.23812. Epub 2019 Apr 23.
PubMed PMID: 31012125.


35: Marafi F, Usmani S, Esmail A. 68Ga-Prostate-Specific Membrane Antigen PET/CT 
in Cholangiocarcinoma: A Potential Biomarker for Targeted Radioligand Therapy?
Clin Nucl Med. 2019 Jul;44(7):e439-e441. doi: 10.1097/RLU.0000000000002563.
PubMed PMID: 30985434.


36: Lindemann ME, Guberina N, Wetter A, Fendler W, Jakoby B, Quick HH. Improving 
68-Ga-PSMA PET/MR hybrid imaging of the prostate with un-renormalized absolute
scatter correction. J Nucl Med. 2019 Apr 12. pii: jnumed.118.224139. doi:
10.2967/jnumed.118.224139. [Epub ahead of print] PubMed PMID: 30979819.


37: Haran C, McBean R, Parsons R, Wong D. Five-year trends of bone scan and
prostate-specific membrane antigen positron emission tomography utilization in
prostate cancer: A retrospective review in a private centre. J Med Imaging Radiat
Oncol. 2019 Aug;63(4):495-499. doi: 10.1111/1754-9485.12885. Epub 2019 Apr 11.
PubMed PMID: 30972933.


38: Basha MAA, Hamed MAG, Hussein O, El-Diasty T, Abdelkhalek YI, Hussein YO,
Alasamer AF, Mohamed HAE, Deen DSE, Tantawy EF, Metwally MI, Zaitoun MMA, Aly SA,
Altohamy JI, Mohamed AEM, Afifi AHM, Harb O. (68)Ga-PSMA-11 PET/CT in newly
diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement.
Abdom Radiol (NY). 2019 Jul;44(7):2545-2556. doi: 10.1007/s00261-019-02006-2.
PubMed PMID: 30963182.


39: Shamni O, Nebeling B, Grievink H, Mishani E. Fine-tuning of the automated
[(18) F]PSMA-1007 radiosynthesis. J Labelled Comp Radiopharm. 2019 May
30;62(6):252-258. doi: 10.1002/jlcr.3732. PubMed PMID: 30941793.


40: Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, 
Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter
RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic 
and tumor-directed therapy for oligometastatic prostate cancer: study protocol
for a phase II trial for veterans with de novo oligometastatic disease. BMC
Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5. PubMed PMID:
30935383; PubMed Central PMCID: PMC6444674.


41: Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B, Trojan L,
Strauss A. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to
detect prostate cancer metastases? Int Braz J Urol. 2019 May-Jun;45(3):459-467.
doi: 10.1590/S1677-5538.IBJU.2018.0305. PubMed PMID: 30901173.


42: Lin CY, Lee MT, Lin CL, Kao CH. Comparing the Staging/Restaging Performance
of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in
Prostate Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2019
May;44(5):365-376. doi: 10.1097/RLU.0000000000002526. PubMed PMID: 30888999.


43: Kretschmer A, Tilki D. [Influence of modern diagnostic methods on the
treatment of nonmetastatic castration-resistant prostate cancer]. Urologe A. 2019
May;58(5):529-534. doi: 10.1007/s00120-019-0904-7. Review. German. PubMed PMID:
30887058.


44: Heidenreich A, Rieke M, Mahjoub S, Pfister D. Management of positive lymph
nodes following radical prostatectomy. Arch Esp Urol. 2019 Mar;72(2):182-191.
Review. PubMed PMID: 30855020.


45: Schwenck J, Olthof SC, Pfannenberg C, Reischl G, Wegener D, Marzec J, Bedke
J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC. Intention to treat
analysis of (68)Ga-PSMA and (11)C-choline PET/CT versus CT for prostate cancer
recurrences after surgery. J Nucl Med. 2019 Mar 8. pii: jnumed.118.224543. doi:
10.2967/jnumed.118.224543. [Epub ahead of print] PubMed PMID: 30850491.


46: Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
More advantages in detecting bone and soft tissue metastases from prostate cancer
using (18)F-PSMA PET/CT. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi:
10.1967/s002449910952. Epub 2019 Mar 7. PubMed PMID: 30843003.


47: McEwan L, McBean R, Yaxley J, Wong D. Unexpected significant findings
non-related to prostate cancer identified using combined prostate-specific
membrane antigen positron emission tomography/CT and diagnostic CT scan in
primary staging for prostate cancer. J Med Imaging Radiat Oncol. 2019
Jun;63(3):318-323. doi: 10.1111/1754-9485.12864. Epub 2019 Mar 6. PubMed PMID:
30840361.


48: Smith CP, Laucis A, Harmon S, Mena E, Lindenberg L, Choyke PL, Turkbey B.
Novel Imaging in Detection of Metastatic Prostate Cancer. Curr Oncol Rep. 2019
Mar 5;21(4):31. doi: 10.1007/s11912-019-0780-8. Review. PubMed PMID: 30834999.


49: Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM.
Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
(68)Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed
Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph 
Node Metastases in Patients with Primary Prostate Cancer. Eur Urol Focus. 2019
Feb 27. pii: S2405-4569(19)30033-1. doi: 10.1016/j.euf.2019.02.013. [Epub ahead
of print] PubMed PMID: 30826284.


50: Artigas C, Flamen P, Charlier F, Levillain H, Wimana Z, Diamand R, Albisinni 
S, Gil T, Velthoven RV, Peltier A, Gestel DV, Roumeguere T, Otte FX. (68)Ga-PSMA 
PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer
recurrence after radical prostatectomy. World J Urol. 2019 Aug;37(8):1535-1542.
doi: 10.1007/s00345-019-02701-1. Epub 2019 Mar 1. PubMed PMID: 30824985.


51: Murphy DG, Padhani AR, Ost P. Adding Colour to the Grey Zone of Advanced
Prostate Cancer. Eur Urol Focus. 2019 Mar;5(2):123-124. doi:
10.1016/j.euf.2019.02.015. Epub 2019 Feb 26. PubMed PMID: 30824379.


52: Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D,
Bolton D, Hofman MS, Lawrentschuk N, Murphy DG. Gallium-68 Prostate-specific
Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated
Diagnostic Utility, Sensitivity, Specificity, and Distribution of
Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and
Meta-analysis. Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095-8. doi:
10.1016/j.eururo.2019.01.049. [Epub ahead of print] Review. PubMed PMID:
30773328.


53: Kuten J, Mabjeesh NJ, Lerman H, Levine C, Barnes S, Even-Sapir E. Ga-PSMA
PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Isr Med Assoc J. 2019 Feb;21(2):100-104. PubMed PMID: 30772960.


54: Lindenberg L, Mena E, Choyke PL, Bouchelouche K. PET imaging in renal cancer.
Curr Opin Oncol. 2019 May;31(3):216-221. doi: 10.1097/CCO.0000000000000518.
PubMed PMID: 30747736; PubMed Central PMCID: PMC6465137.


55: Rowe SP, Gorin MA, Pomper MG. Imaging of Prostate-Specific Membrane Antigen
with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical
Applications. Annu Rev Med. 2019 Jan 27;70:461-477. doi:
10.1146/annurev-med-062117-073027. PubMed PMID: 30691373.


56: Gouveia PB, Violante LCS, Teixeira RJV, da Silva Trindade Duarte LH.
68Ga-PSMA Uptake in Prostate Cancer Sciatic Nerve Metastasis. Clin Nucl Med. 2019
Apr;44(4):e301-e302. doi: 10.1097/RLU.0000000000002476. PubMed PMID: 30688745.


57: Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A,
Ingrosso G, Liefhooghe N, Miralbell R, Siva S, Van der Eecken K, Ost P.
Oligometastatic prostate cancer: The game is afoot. Cancer Treat Rev. 2019
Feb;73:84-90. doi: 10.1016/j.ctrv.2019.01.005. Epub 2019 Jan 17. Review. PubMed
PMID: 30684842.


58: Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G,
Delahunt B, Egevad L, McEwan L, Wong D. Outcomes of Primary Lymph Node Staging of
Intermediate and High Risk Prostate Cancer with (68)Ga-PSMA Positron Emission
Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic
Lymph Node Pathology. J Urol. 2019 Apr;201(4):815-820. doi:
10.1097/JU.0000000000000053. PubMed PMID: 30672842.


59: Moghul M, Somani B, Lane T, Vasdev N, Chaplin B, Peedell C, KandaSwamy GV,
Rai BP. Detection rates of recurrent prostate cancer: (68)Gallium (Ga)-labelled
prostate-specific membrane antigen versus choline PET/CT scans. A systematic
review. Ther Adv Urol. 2019 Jan 8;11:1756287218815793. doi:
10.1177/1756287218815793. eCollection 2019 Jan-Dec. Review. PubMed PMID:
30671137; PubMed Central PMCID: PMC6329022.


60: Barbosa FG, Queiroz MA, Nunes RF, Viana PCC, Marin JFG, Cerri GG, Buchpiguel 
CA. Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and
Atypical Patterns of Spread. Radiographics. 2019 Jan-Feb;39(1):186-212. doi:
10.1148/rg.2019180079. PubMed PMID: 30620699.


61: Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I. A
Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography 
(PET) in Renal Cell Carcinoma (RCC). Mol Imaging Biol. 2019 Jan 7. doi:
10.1007/s11307-018-01307-0. [Epub ahead of print] PubMed PMID: 30617728.


62: Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlin T, Bengel FM, Ross
TL, Wester HJ, Derlin K, Kuczyk MA, von Klot CAJ, Christiansen H, Henkenberens C.
Comparison of (68) Ga-PSMA ligand PET/CT versus conventional cross-sectional
imaging for target volume delineation for metastasis-directed radiotherapy for
metachronous lymph node metastases from prostate cancer. Strahlenther Onkol. 2019
May;195(5):420-429. doi: 10.1007/s00066-018-1417-9. Epub 2019 Jan 4. PubMed PMID:
30610354.


63: Polverari G, Ceci F, Calderoni L, Cervati V, Farolfi A, Castellucci P, Fanti 
S. Male Breast Cancer Detected by (68)Ga-PSMA-11 PET/CT in a Patient With
Prostate Cancer With Pelvic Lymph Node Metastasis. Clin Genitourin Cancer. 2019
Apr;17(2):154-156. doi: 10.1016/j.clgc.2018.11.020. Epub 2018 Dec 4. PubMed PMID:
30587404.


64: Muteganya R, Goldman S, Aoun F, Roumeguère T, Albisinni S. Current Imaging
Techniques for Lymph Node Staging in Prostate Cancer: A Review. Front Surg. 2018 
Dec 7;5:74. doi: 10.3389/fsurg.2018.00074. eCollection 2018. Review. PubMed PMID:
30581819; PubMed Central PMCID: PMC6293868.


65: Pereira Mestre R, Treglia G, Ferrari M, Pascale M, Mazzara C, Azinwi NC,
Llado' A, Stathis A, Giovanella L, Roggero E. Correlation between PSA kinetics
and PSMA-PET in prostate cancer restaging: A meta-analysis. Eur J Clin Invest.
2019 Mar;49(3):e13063. doi: 10.1111/eci.13063. Epub 2019 Jan 11. PubMed PMID:
30580449.


66: Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M 3rd,
Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA. Impact of Staging
(68)Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate
Cancer. Urology. 2019 Mar;125:154-162. doi: 10.1016/j.urology.2018.09.038. Epub
2018 Dec 21. PubMed PMID: 30580002.


67: Heidenreich A. WITHDRAWN: Impact of Staging 68Ga-PSMA-11 PET scans on
radiation treatment plans in patients with prostate cancer by Thomas Hope et al. 
Urology. 2018 Dec 21. pii: S0090-4295(18)31326-8. doi:
10.1016/j.urology.2018.12.011. [Epub ahead of print] PubMed PMID: 30580001.


68: Lohaus F, Zöphel K, Löck S, Wirth M, Kotzerke J, Krause M, Baumann M, Troost 
EGC, Hölscher T. Can Local Ablative Radiotherapy Revert Castration-resistant
Prostate Cancer to an Earlier Stage of Disease? Eur Urol. 2019 Apr;75(4):548-551.
doi: 10.1016/j.eururo.2018.11.050. Epub 2018 Dec 18. PubMed PMID: 30578119.


69: Nandurkar R, van Leeuwen P, Stricker P, Woo H, Kooner R, Yuen C, O'Neill G,
Ende D, Cusick T, Ho B, Hickey A, Emmett L. (68)Ga-HBEDD PSMA-11 PET/CT staging
prior to radical prostatectomy in prostate cancer patients: Diagnostic and
predictive value for the biochemical response to surgery. Br J Radiol. 2019
Mar;92(1095):20180667. doi: 10.1259/bjr.20180667. Epub 2019 Jan 23. PubMed PMID: 
30563350; PubMed Central PMCID: PMC6541197.


70: Schmidt-Hegemann NS, Eze C, Li M, Rogowski P, Schaefer C, Stief C, Buchner A,
Zamboglou C, Fendler WP, Ganswindt U, Cyran C, Bartenstein P, Belka C, Ilhan H.
Impact of (68)Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer 
in Comparison to CT: A Retrospective Analysis. J Nucl Med. 2019
Jul;60(7):963-970. doi: 10.2967/jnumed.118.220855. Epub 2018 Dec 14. PubMed PMID:
30552203; PubMed Central PMCID: PMC6604695.


71: Klingenberg S, Jochumsen MR, Nielsen TF, Bouchelouche K. 68Ga-PSMA Uptake in 
Anal Fistula on PET/CT Scan. Clin Nucl Med. 2019 Jan;44(1):e54-e56. doi:
10.1097/RLU.0000000000002370. PubMed PMID: 30540600.


72: Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis
of (68)Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by 
Histopathology. J Nucl Med. 2019 Jun;60(6):786-793. doi:
10.2967/jnumed.118.219501. Epub 2018 Dec 7. PubMed PMID: 30530831; PubMed Central
PMCID: PMC6581235.


73: Gupta M, Choudhury PS, Rawal S, Goel HC, Talwar V, Singh A, Sahoo SK. Initial
risk stratification and staging in prostate cancer with prostatic-specific
membrane antigen positron emission tomography/computed tomography: A
first-stop-shop. World J Nucl Med. 2018 Oct-Dec;17(4):261-269. doi:
10.4103/wjnm.WJNM_79_17. PubMed PMID: 30505224; PubMed Central PMCID: PMC6216727.


74: Sakthivel P, Prashanth A, Thakar A, Kumar R, Kumar R. Juvenile Nasal
Angiofibroma on 68Ga-PSMA PET/CT: Opening New Frontiers. Clin Nucl Med. 2019
Feb;44(2):e118-e119. doi: 10.1097/RLU.0000000000002387. PubMed PMID: 30516685.


75: Özülker F. Efficacy of early imaging with (68)Ga-PSMA-I&T in the
discrimination of pelvic lesions in prostate cancer patients. Rev Esp Med Nucl
Imagen Mol. 2019 Mar - Apr;38(2):100-105. doi: 10.1016/j.remn.2018.06.006. Epub
2018 Dec 1. English, Spanish. PubMed PMID: 30514659.


76: Bialek EJ, Malkowski B. Celiac ganglia: can they be misinterpreted on
multimodal 68Ga-PSMA-11 PET/MR? Nucl Med Commun. 2019 Feb;40(2):175-184. doi:
10.1097/MNM.0000000000000944. PubMed PMID: 30480555; PubMed Central PMCID:
PMC6380442.


77: Tangel MR, Rastinehad AR. Advances in prostate cancer imaging. F1000Res. 2018
Aug 24;7. pii: F1000 Faculty Rev-1337. doi: 10.12688/f1000research.14498.1.
eCollection 2018. Review. PubMed PMID: 30467517; PubMed Central PMCID:
PMC6113878.


78: Rayn KN, Elnabawi YA, Sheth N. Clinical implications of PET/CT in prostate
cancer management. Transl Androl Urol. 2018 Oct;7(5):844-854. doi:
10.21037/tau.2018.08.26. Review. PubMed PMID: 30456187; PubMed Central PMCID:
PMC6212623.


79: Czarniecki M, Mena E, Lindenberg L, Cacko M, Harmon S, Radtke JP, Giesel F,
Turkbey B, Choyke PL. Keeping up with the prostate-specific membrane antigens
(PSMAs): an introduction to a new class of positron emission tomography (PET)
imaging agents. Transl Androl Urol. 2018 Oct;7(5):831-843. doi:
10.21037/tau.2018.08.03. Review. PubMed PMID: 30456186; PubMed Central PMCID:
PMC6212618.


80: Demirci E, Kabasakal L, Şahin OE, Akgün E, Gültekin MH, Doğanca T, Tuna MB,
Öbek C, Kiliç M, Esen T, Kural AR. Can SUVmax values of Ga-68-PSMA PET/CT scan
predict the clinically significant prostate cancer? Nucl Med Commun. 2019
Jan;40(1):86-91. doi: 10.1097/MNM.0000000000000942. PubMed PMID: 30395048; PubMed
Central PMCID: PMC6282663.


81: Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer
A, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R, Ost P,
Briganti A; EAU-YAU Prostate Cancer Working Group. Salvage Lymph Node Dissection 
for Nodal Recurrent Prostate Cancer: A Systematic Review. Eur Urol. 2018 Oct 31. 
pii: S0302-2838(18)30836-4. doi: 10.1016/j.eururo.2018.10.041. [Epub ahead of
print] Review. PubMed PMID: 30391078.


82: Malik D, Sood A, Mittal BR, Singh H, Basher RK, Shukla J, Bhattacharya A,
Singh SK. Nonspecific Uptake of (68)Ga-Prostate-Specific Membrane Antigen in
Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed 
Tomography Imaging: A Pictorial Assay and Review of Literature. Indian J Nucl
Med. 2018 Oct-Dec;33(4):317-325. doi: 10.4103/ijnm.IJNM_81_18. PubMed PMID:
30386054; PubMed Central PMCID: PMC6194764.


83: Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, Pirmisashvili
N, Ben-Haim S. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of
disease, benign findings and pitfalls. Cancer Imaging. 2018 Nov 1;18(1):39. doi: 
10.1186/s40644-018-0175-3. PubMed PMID: 30382889; PubMed Central PMCID:
PMC6211573.


84: Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N. PSMA
PET applications in the prostate cancer journey: from diagnosis to theranostics. 
World J Urol. 2019 Jul;37(7):1255-1261. doi: 10.1007/s00345-018-2524-z. Epub 2018
Oct 29. PubMed PMID: 30374609.


85: Ries M, Khreish F, Veith C, von den Hoff J, Ezziddin S. Large Paraesophageal 
Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on
68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate
Cancer. Clin Nucl Med. 2019 Feb;44(2):153-154. doi: 10.1097/RLU.0000000000002359.
PubMed PMID: 30371596.


86: Lovegrove CE, Matanhelia M, Randeva J, Eldred-Evans D, Tam H, Miah S, Winkler
M, Ahmed HU, Shah TT. Prostate imaging features that indicate benign or malignant
pathology on biopsy. Transl Androl Urol. 2018 Sep;7(Suppl 4):S420-S435. doi:
10.21037/tau.2018.07.06. Review. PubMed PMID: 30363462; PubMed Central PMCID:
PMC6178322.


87: Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
(68)Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different
clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging.
2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22. PubMed
PMID: 30350010.


88: Mirzaei S, Knoll P, Zandieh S. [The role of molecular imaging (PET-CT) in the
diagnostic and treatment pf prostate cancer]. Wien Med Wochenschr. 2019
Feb;169(1-2):12-14. doi: 10.1007/s10354-018-0668-5. Epub 2018 Oct 22. Review.
German. PubMed PMID: 30349972.


89: Castellucci P, Nanni C, Ambrosini V. Nuclear Medicine Imaging of Prostate
Cancer in the Elderly. Semin Nucl Med. 2018 Nov;48(6):541-547. doi:
10.1053/j.semnuclmed.2018.07.004. Epub 2018 Aug 8. Review. PubMed PMID: 30322480.


90: Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer 
T, Graefen M. Metastases-yield and Prostate-specific Antigen Kinetics Following
Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between
Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided
Surgery. Eur Urol Focus. 2019 Jan;5(1):50-53. doi: 10.1016/j.euf.2018.09.014.
Epub 2018 Oct 3. PubMed PMID: 30292421.


91: Barbosa FG, Queiroz MA, Nunes RF, Marin JFG, Buchpiguel CA, Cerri GG.
Clinical perspectives of PSMA PET/MRI for prostate cancer. Clinics (Sao Paulo).
2018 Sep 21;73(suppl 1):e586s. doi: 10.6061/clinics/2018/e586s. Review. PubMed
PMID: 30281701; PubMed Central PMCID: PMC6142859.


92: Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF. 68Ga-PSMA-11 PET/CT
in Newly Diagnosed Prostate Adenocarcinoma. Clin Nucl Med. 2018
Dec;43(12):e422-e427. doi: 10.1097/RLU.0000000000002289. PubMed PMID: 30273204.


93: Gauvin S, Rompré-Brodeur A, Chaussé G, Anidjar M, Bladou F, Probst S.
(18)F-fluorocholine positron emission tomography-computed tomography ((18)F-FCH
PET/CT) for staging of high-risk prostate cancer patients. Can Urol Assoc J. 2019
Apr;13(4):84-91. doi: 10.5489/cuaj.5142. Epub 2018 Sep 27. PubMed PMID: 30273114;
PubMed Central PMCID: PMC6456350.


94: Afaq A, Bomanji J. Prostate-specific membrane antigen positron emission
tomography in the management of recurrent prostate cancer. Br Med Bull. 2018 Dec 
1;128(1):37-48. doi: 10.1093/bmb/ldy032. Review. PubMed PMID: 30272121.


95: Kim SJ, Lee SW, Ha HK. Diagnostic Performance of Radiolabeled
Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed
Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to
High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis. Urol
Int. 2019;102(1):27-36. doi: 10.1159/000493169. Epub 2018 Sep 28. PubMed PMID:
30269140.


96: Schiavina R, Chessa F, Borghesi M, Gaudiano C, Bianchi L, Corcioni B,
Castellucci P, Ceci F, Ceravolo I, Barchetti G, Del Monte M, Campa R, Catalano C,
Panebianco V, Nanni C, Fanti S, Minervini A, Porreca A, Brunocilla E.
State-of-the-art imaging techniques in the management of preoperative staging and
re-staging of prostate cancer. Int J Urol. 2019 Jan;26(1):18-30. doi:
10.1111/iju.13797. Epub 2018 Sep 20. Review. PubMed PMID: 30238516.


97: Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, Dunglison N,
Gardiner RA, Yaxley J. Improved specificity with (68)Ga PSMA PET/CT to detect
clinically significant lesions "invisible" on multiparametric MRI of the
prostate: a single institution comparative analysis with radical prostatectomy
histology. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):20-30. doi:
10.1007/s00259-018-4160-7. Epub 2018 Sep 19. PubMed PMID: 30229528.


98: Zacho HD, Petersen LJ. Bone Flare to Androgen Deprivation Therapy in
Metastatic, Hormone-Sensitive Prostate Cancer on 68Ga-Prostate-Specific Membrane 
Antigen PET/CT. Clin Nucl Med. 2018 Nov;43(11):e404-e406. doi:
10.1097/RLU.0000000000002273. PubMed PMID: 30222680.


99: Sasikumar A, Joy A, Pillai AMR, Oommen KE, Somarajan S, Raman VK, Thomas R,
Dinesh D. Gallium 68-PSMA PET/CT for lesion characterization in suspected cases
of prostate carcinoma. Nucl Med Commun. 2018 Nov;39(11):1013-1021. doi:
10.1097/MNM.0000000000000906. PubMed PMID: 30216228.


100: Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J,
Al-Daghmin A, Salah S. [(68)Ga]PSMA PET/CT Improves Initial Staging and
Management Plan of Patients with High-Risk Prostate Cancer. Mol Imaging Biol.
2019 Jun;21(3):574-581. doi: 10.1007/s11307-018-1278-8. PubMed PMID: 30215174.


101: Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, Wester 
HJ, Derlin K, Kuczyk MA, Christiansen H, Henkenberens C. Patterns of Progression 
After (68)Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate
Cancer. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104. doi:
10.1016/j.ijrobp.2018.08.066. Epub 2018 Sep 7. PubMed PMID: 30201438.


102: Ferda J, Ferdová E, Tupý R, Baxa J. Hybrid imaging PET/MR in prostatic
carcinoma. Cas Lek Cesk. Summer 2018;157(4):169-174. PubMed PMID: 30189739.


103: Meyer AR, Joice GA, Allaf ME, Rowe SP, Gorin MA. Integration of
PSMA-targeted PET imaging into the armamentarium for detecting clinically
significant prostate cancer. Curr Opin Urol. 2018 Nov;28(6):493-498. doi:
10.1097/MOU.0000000000000549. Review. PubMed PMID: 30188333.


104: Oh SW, Cheon GJ. Prostate-Specific Membrane Antigen PET Imaging in Prostate 
Cancer: Opportunities and Challenges. Korean J Radiol. 2018
Sep-Oct;19(5):819-831. doi: 10.3348/kjr.2018.19.5.819. Epub 2018 Aug 6. Review.
PubMed PMID: 30174470; PubMed Central PMCID: PMC6082771.


105: Marzouk K, Ehdaie B. New Imaging Techniques in Prostate Cancer. Cancer Treat
Res. 2018;175:1-13. doi: 10.1007/978-3-319-93339-9_1. PubMed PMID: 30168115.


106: Dekker I, van der Leest M, van Rijk MC, Gerritsen WR, Arens AIJ. 68Ga-PSMA
Uptake in Angiolipoma. Clin Nucl Med. 2018 Oct;43(10):757-758. doi:
10.1097/RLU.0000000000002236. PubMed PMID: 30153142.


107: Wong HS, Leung J, Bartholomeusz D, Sutherland P, Le H, Nottage M, Iankov I, 
Chang JH. Comparative study between (68) Ga-prostate-specific membrane antigen
positron emission tomography and conventional imaging in the initial staging of
prostate cancer. J Med Imaging Radiat Oncol. 2018 Dec;62(6):816-822. doi:
10.1111/1754-9485.12791. Epub 2018 Aug 28. PubMed PMID: 30152050.


108: Akdemir EN, Tuncel M, Akyol F, Bilen CY, Baydar DE, Karabulut E, Ozen H,
Caglar M. (68)Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with
recurrent prostate cancer. World J Urol. 2019 May;37(5):813-821. doi:
10.1007/s00345-018-2460-y. Epub 2018 Aug 27. PubMed PMID: 30151600.


109: Grubmüller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR,
Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N,
Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF,
Hacker M, Hartenbach M. PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging 
Performance and Clinical Impact. Clin Cancer Res. 2018 Dec 15;24(24):6300-6307.
doi: 10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23. PubMed PMID: 30139879.


110: Fraum TJ, Ludwig DR, Kim EH, Schroeder P, Hope TA, Ippolito JE. Prostate
cancer PET tracers: essentials for the urologist. Can J Urol. 2018
Aug;25(4):9371-9383. Review. PubMed PMID: 30125515.


111: Sanli Y, Sanli O, Has Simsek D, Subramaniam RM. 68Ga-PSMA PET/CT and PET/MRI
in high-risk prostate cancer patients. Nucl Med Commun. 2018 Oct;39(10):871-880. 
doi: 10.1097/MNM.0000000000000888. Review. PubMed PMID: 30124601.


112: Evangelista L, Basso U, Maruzzo M, Novara G. The Role of Radiolabeled
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed
Tomography for the Evaluation of Renal Cancer. Eur Urol Focus. 2018 Aug 14. pii: 
S2405-4569(18)30223-2. doi: 10.1016/j.euf.2018.08.004. [Epub ahead of print]
Review. PubMed PMID: 30120074.


113: Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, Maes
A, Mokgoro NP, Van de Wiele C, Vorster M, Sathekge MM. (68)Ga-PSMA PET/CT
Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate
Cancer: A Fait Accompli? Clin Genitourin Cancer. 2018 Oct;16(5):392-401. doi:
10.1016/j.clgc.2018.07.009. Epub 2018 Jul 21. PubMed PMID: 30120038.


114: Rauscher I, Eiber M, Weber WA, Gschwend JE, Horn T, Maurer T.
Positron-emission tomography imaging in urological oncology: Current aspects and 
developments. Int J Urol. 2018 Nov;25(11):912-921. doi: 10.1111/iju.13779. Epub
2018 Aug 13. Review. PubMed PMID: 30103285.


115: Malik D, Mittal BR, Kumar R, Singh H, Bhattacharya A, Singh SK. Incidental
Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific
Membrane Antigen PET/CT. Clin Nucl Med. 2018 Sep;43(9):e334-e335. doi:
10.1097/RLU.0000000000002189. PubMed PMID: 30080189.


116: Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ,
Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev
V, Reiter RE, Divgi C, Yu EY; RADAR III Group. A Clinician's Guide to Next
Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol.
2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164. Review. PubMed PMID:
30077557.


117: van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit
EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
Gallium-68-prostate-specific membrane antigen ((68) Ga-PSMA) positron emission
tomography (PET)/computed tomography (CT) predicts complete biochemical response 
from radical prostatectomy and lymph node dissection in intermediate- and
high-risk prostate cancer. BJU Int. 2019 Jul;124(1):62-68. doi:
10.1111/bju.14506. Epub 2019 Apr 7. PubMed PMID: 30074667.


118: Mix M, Reichel K, Stoykow C, Bartholomä M, Drendel V, Gourni E, Wetterauer
U, Schultze-Seemann W, Meyer PT, Jilg CA. Performance of (111)In-labelled PSMA
ligand in patients with nodal metastatic prostate cancer: correlation between
tracer uptake and histopathology from lymphadenectomy. Eur J Nucl Med Mol
Imaging. 2018 Nov;45(12):2062-2070. doi: 10.1007/s00259-018-4094-0. Epub 2018 Jul
30. PubMed PMID: 30062606.


119: Mandel P, Tilki D, Chun FK, Pristupa E, Graefen M, Klutmann S, Budäus L,
Steuber T. Accuracy of (68)Ga-Prostate-specific Membrane Antigen Positron
Emission Tomography for the Detection of Lymph Node Metastases Before Salvage
Lymphadenectomy. Eur Urol Focus. 2018 Jul 23. pii: S2405-4569(18)30191-3. doi:
10.1016/j.euf.2018.07.025. [Epub ahead of print] PubMed PMID: 30049657.


120: Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller
K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer
V, Kopka K, Eiber M. Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients
with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J
Nucl Med. 2019 Mar;60(3):362-368. doi: 10.2967/jnumed.118.212233. Epub 2018 Jul
24. PubMed PMID: 30042163; PubMed Central PMCID: PMC6424235.


121: Pedersen MA, Bouchelouche K, Vendelbo MH. 68Ga-PSMA Uptake in Middle Lobe
Syndrome. Clin Nucl Med. 2018 Oct;43(10):e376-e377. doi:
10.1097/RLU.0000000000002213. PubMed PMID: 30036250.


122: Veliev EI, Tomilov AA, Goncharuk DA, Bogdanov AB, Golubtsova EN. [Diagnostic
performance of 68GA-PSMA PET/CTin patients with prostate cancer]. Urologiia. 2018
Jul;(3):105-110. Russian. PubMed PMID: 30035428.


123: Hofman MS, Iravani A, Nzenza T, Murphy DG. Advances in Urologic Imaging:
Prostate-Specific Membrane Antigen Ligand PET Imaging. Urol Clin North Am. 2018
Aug;45(3):503-524. doi: 10.1016/j.ucl.2018.03.016. Epub 2018 Jun 15. Review.
PubMed PMID: 30031469.


124: Fankhauser CD, Poyet C, Kroeze SGC, Kranzbühler B, Schüler HIG, Guckenberger
M, Kaufmann PA, Hermanns T, Burger IA. Current and potential future role of
PSMA-PET in patients with castration-resistant prostate cancer. World J Urol.
2019 Mar;37(3):457-467. doi: 10.1007/s00345-018-2408-2. Epub 2018 Jul 20. Review.
PubMed PMID: 30030659.


125: Ege Aktas G, Yürüt Çaloğlu V, Akdere H, Tutuğ BB, Altun GD. Biochemical
Recurrence of Prostate Cancer Presenting as Solitary Testicular Metastasis on
68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission
Tomography/Computed Tomography. Clin Nucl Med. 2018 Sep;43(9):699-700. doi:
10.1097/RLU.0000000000002204. PubMed PMID: 30015663.


126: Komek H, Can C, Yilmaz U, Altindag S. Prognostic value of 68 Ga PSMA I&T
PET/CT SUV parameters on survival outcome in advanced prostat cancer. Ann Nucl
Med. 2018 Oct;32(8):542-552. doi: 10.1007/s12149-018-1277-5. Epub 2018 Jul 13.
PubMed PMID: 30006752.


127: Singh D, Horneman R, Nagra NK. More than the prostate: Intrapancreatic
accessory spleen and papillary thyroid cancer detected with (18)F-PSMA PET/CT.
Hell J Nucl Med. 2018 May-Aug;21(2):145-147. doi: 10.1967/s002449910805. Epub
2018 Jul 12. PubMed PMID: 30006647.


128: Sathianathen NJ, Butaney M, Konety BR. The utility of PET-based imaging for 
prostate cancer biochemical recurrence: a systematic review and meta-analysis.
World J Urol. 2019 Jul;37(7):1239-1249. doi: 10.1007/s00345-018-2403-7. Epub 2018
Jul 12. PubMed PMID: 30003375.


129: Rogasch JM, Cash H, Zschaeck S, Elezkurtaj S, Brenner W, Hamm B, Makowski M,
Amthauer H, Furth C, Baur ADJ. Ga-68-PSMA PET/CT in treatment-naïve patients with
prostate cancer: Which clinical parameters and risk stratification systems best
predict PSMA-positive metastases? Prostate. 2018 Jul 5. doi: 10.1002/pros.23685. 
[Epub ahead of print] PubMed PMID: 29978529.


130: Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, Merkle J, 
Herfarth K, Kopka K, Choyke PL, Holland-Letz T, Haberkorn U, Debus J, Giesel FL. 
(68)Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications
for Radiotherapeutic Management in 121 Patients. J Nucl Med. 2018 Jul 5. pii:
jnumed.118.211086. doi: 10.2967/jnumed.118.211086. [Epub ahead of print] PubMed
PMID: 29976697.


131: van Kalmthout LWM, Lam MGEH, de Keizer B, Krijger GC, Ververs TFT, de Roos
R, Braat AJAT. Impact of external cooling with icepacks on (68)Ga-PSMA uptake in 
salivary glands. EJNMMI Res. 2018 Jul 3;8(1):56. doi: 10.1186/s13550-018-0408-2. 
PubMed PMID: 29971556; PubMed Central PMCID: PMC6029992.


132: Dundee P, Gross T, Moran D, Ryan A, Ballok Z, Peters J, Costello AJ.
Ga-labeled Prostate-specific Membrane Antigen Ligand-positron-emission
Tomography: Still Just the Tip of the Iceberg. Urology. 2018 Oct;120:187-191.
doi: 10.1016/j.urology.2018.06.029. Epub 2018 Jun 28. PubMed PMID: 29964126.


133: Perveen G, Arora G, Damle NA, Prabhu M, Arora S, Tripathi M, Bal C, Kumar P,
Kumar R, Singh P, Das CJ, Passah A. Can Early Dynamic Positron Emission
Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in
(68)Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma? Indian J Nucl
Med. 2018 Jul-Sep;33(3):202-208. doi: 10.4103/ijnm.IJNM_32_18. PubMed PMID:
29962715; PubMed Central PMCID: PMC6011556.


134: Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C,
Rowe SP. Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT
and PET/MRI: Current and Future Applications. AJR Am J Roentgenol. 2018
Aug;211(2):286-294. doi: 10.2214/AJR.18.19957. Epub 2018 Jun 27. Review. PubMed
PMID: 29949419.


135: Arsenault F, Beauregard JM, Pouliot F. Prostate-specific membrane antigen
for prostate cancer theranostics: from imaging to targeted therapy. Curr Opin
Support Palliat Care. 2018 Sep;12(3):359-365. doi: 10.1097/SPC.0000000000000357. 
Review. PubMed PMID: 29939893.


136: Cantiello F, Crocerossa F, Russo GI, Gangemi V, Ferro M, Vartolomei MD,
Lucarelli G, Mirabelli M, Scafuro C, Ucciero G, De Cobelli O, Morgia G, Damiano
R, Cascini GL. Comparison Between (64)Cu-PSMA-617 PET/CT and (18)F-Choline PET/CT
Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clin
Genitourin Cancer. 2018 Oct;16(5):385-391. doi: 10.1016/j.clgc.2018.05.014. Epub 
2018 Jun 4. PubMed PMID: 29937067.


137: Beuthien-Baumann B, Koerber SA. PET imaging in adaptive radiotherapy of
prostate tumors. Q J Nucl Med Mol Imaging. 2018 Dec;62(4):404-410. doi:
10.23736/S1824-4785.18.03080-7. Epub 2018 Jun 4. Review. PubMed PMID: 29869483.


138: Berger I, Annabattula C, Lewis J, Shetty DV, Kam J, Maclean F, Arianayagam
M, Canagasingham B, Ferguson R, Khadra M, Ko R, Winter M, Loh H, Varol C.
(68)Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging:
correlation with final histopathology. Prostate Cancer Prostatic Dis. 2018
Jun;21(2):204-211. doi: 10.1038/s41391-018-0048-7. Epub 2018 Jun 1. PubMed PMID: 
29858591.


139: Muehlematter UJ, Rupp NJ, Mueller J, Eberli D, Burger IA. 68Ga-PSMA
PET/MR-Positive, Histopathology-Proven Prostate Cancer in a Patient With Negative
Multiparametric Prostate MRI. Clin Nucl Med. 2018 Aug;43(8):e282-e284. doi:
10.1097/RLU.0000000000002143. PubMed PMID: 29847319.


140: Thalgott M, Düwel C, Rauscher I, Heck MM, Haller B, Gafita A, Gschwend JE,
Schwaiger M, Maurer T, Eiber M. One-Stop-Shop Whole-Body (68)Ga-PSMA-11 PET/MRI
Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk
Prostate Cancer. J Nucl Med. 2018 Dec;59(12):1850-1856. doi:
10.2967/jnumed.117.207696. Epub 2018 May 24. PubMed PMID: 29794224.


141: Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, Giesel F,
Ghanouni P, Daniel B, Loening AM, Sonn GA, Iagaru A. Gallium 68 PSMA-11 PET/MR
Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. Radiology.
2018 Aug;288(2):495-505. doi: 10.1148/radiol.2018172232. Epub 2018 May 22. PubMed
PMID: 29786490.


142: Sevcenco S, Klingler HC, Eredics K, Friedl A, Schneeweiss J, Knoll P, Kunit 
T, Lusuardi L, Mirzaei S. Application of Cu-64 NODAGA-PSMA PET in Prostate
Cancer. Adv Ther. 2018 Jun;35(6):779-784. doi: 10.1007/s12325-018-0711-3. Epub
2018 May 17. PubMed PMID: 29777523.


143: Fodor A, Lancia A, Ceci F, Picchio M, Hoyer M, Jereczek-Fossa BA, Ost P,
Castellucci P, Incerti E, Di Muzio N, Ingrosso G. Oligorecurrent prostate cancer 
limited to lymph nodes: getting our ducks in a row. World J Urol. 2018 May 11.
doi: 10.1007/s00345-018-2322-7. [Epub ahead of print] PubMed PMID: 29752513.


144: Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA,
Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. A prospective randomized
multicentre study of the impact of gallium-68 prostate-specific membrane antigen 
(PSMA) PET/CT imaging for staging high-risk prostate cancer prior to
curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3. PubMed
PMID: 29726071.


145: Cuccurullo V, Di Stasio GD, Mansi L. Nuclear Medicine in Prostate Cancer: A 
New Era for Radiotracers. World J Nucl Med. 2018 Apr-Jun;17(2):70-78. doi:
10.4103/wjnm.WJNM_54_17. Review. PubMed PMID: 29719480; PubMed Central PMCID:
PMC5905261.


146: Gupta M, Choudhury PS, Rawal S, Gupta G. Incremental value of
68-gallium-prostate-specific membrane antigen positron emission
tomography/computed tomography in patients with abnormal prostate-specific
antigen and benign transrectal ultrasound biopsy. Urol Ann. 2018
Apr-Jun;10(2):150-153. doi: 10.4103/UA.UA_55_17. PubMed PMID: 29719325; PubMed
Central PMCID: PMC5907322.


147: Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK. 68Ga-Labeled
PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove "PS" From
PSMA? Clin Nucl Med. 2018 Jul;43(7):529-532. doi: 10.1097/RLU.0000000000002103.
PubMed PMID: 29688950.


148: De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M,
Cavalleri S, Salgarello M, Alongi F. Could 68-Ga PSMA PET/CT become a new tool in
the decision-making strategy of prostate cancer patients with biochemical
recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
Radiol Med. 2018 Sep;123(9):719-725. doi: 10.1007/s11547-018-0890-7. Epub 2018
Apr 23. PubMed PMID: 29687208.


149: Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter
J, Byrne K, Kneebone A. (68) Ga-PSMA-PET/CT staging prior to definitive radiation
treatment for prostate cancer. Asia Pac J Clin Oncol. 2018 Aug;14(4):343-346.
doi: 10.1111/ajco.12872. Epub 2018 Apr 16. PubMed PMID: 29663686.


150: Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter 
RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols 
NG. Potential Impact of (68)Ga-PSMA-11 PET/CT on the Planning of Definitive
Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 Nov;59(11):1714-1721.
doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13. PubMed PMID: 29653978; PubMed
Central PMCID: PMC6225538.


151: Perveen G, Arora G, Damle NA, Prabhu M, Arora S, Tripathi M, Bal C, Kumar P,
Kumar R, Singh P. Role of Early Dynamic Positron Emission Tomography/Computed
Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with 
Adenocarcinoma Prostate: Initial Results. Indian J Nucl Med. 2018
Apr-Jun;33(2):112-117. doi: 10.4103/ijnm.IJNM_8_18. PubMed PMID: 29643670; PubMed
Central PMCID: PMC5883427.


152: Cambeiro M, Calvo FA. [Radiotherapy for local disease in metastatic prostate
cancer.]. Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish. PubMed PMID:
29633951.


153: Werner RA, Andree C, Javadi MS, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin
MA, Rowe SP, Pienta KJ. A Voice From the Past: Rediscovering the Virchow Node
With Prostate-specific Membrane Antigen-targeted (18)F-DCFPyL Positron Emission
Tomography Imaging. Urology. 2018 Jul;117:18-21. doi:
10.1016/j.urology.2018.03.030. Epub 2018 Apr 4. PubMed PMID: 29626569; PubMed
Central PMCID: PMC6030443.


154: Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, 
van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, 
Eiber M. (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided
Surgery in Recurrent Prostate Cancer. Eur Urol. 2019 Apr;75(4):659-666. doi:
10.1016/j.eururo.2018.03.013. Epub 2018 Apr 4. PubMed PMID: 29625755.


155: Clarebrough E, Duncan C, Christidis D, Lavoipierre A, Lawrentschuk N.
PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a 
targeted approach. World J Urol. 2019 Jul;37(7):1251-1254. doi:
10.1007/s00345-018-2282-y. Epub 2018 Apr 3. Review. PubMed PMID: 29616296.


156: Derlin T, Grünwald V, Steinbach J, Wester HJ, Ross TL. Molecular Imaging in 
Oncology Using Positron Emission Tomography. Dtsch Arztebl Int. 2018 Mar
16;115(11):175-181. doi: 10.3238/arztebl.2018.0175. PubMed PMID: 29607803; PubMed
Central PMCID: PMC5913576.


157: Bjurlin MA, Turkbey B, Rosenkrantz AB, Gaur S, Choyke PL, Taneja SS. Imaging
the High-risk Prostate Cancer Patient: Current and Future Approaches to Staging. 
Urology. 2018 Jun;116:3-12. doi: 10.1016/j.urology.2017.12.001. Epub 2018 Mar 12.
Review. PubMed PMID: 29545055.


158: Rahbar K, Afshar-Oromieh A, Bögemann M, Wagner S, Schäfers M, Stegger L,
Weckesser M. (18)F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with
prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J
Nucl Med Mol Imaging. 2018 Jul;45(8):1329-1334. doi: 10.1007/s00259-018-3989-0.
Epub 2018 Mar 14. PubMed PMID: 29541812.


159: Jochumsen MR, Madsen MA, Gammelgaard L, Bouchelouche K. Lumbar Osteophyte
Avid on 68Ga-Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med. 2018
Jun;43(6):456-457. doi: 10.1097/RLU.0000000000002065. PubMed PMID: 29538033.


160: Taneja S, Jena A, Taneja R, Singh A, Ahuja A. Effect of Combined
(68)Ga-PSMAHBED-CC Uptake Pattern and Multiparametric MRI Derived With
Simultaneous PET/MRI in the Diagnosis of Primary Prostate Cancer: Initial
Experience. AJR Am J Roentgenol. 2018 Jun;210(6):1338-1345. doi:
10.2214/AJR.17.18881. Epub 2018 Mar 12. PubMed PMID: 29528713.


161: Pizzuto DA, Müller J, Mühlematter U, Rupp NJ, Töpfer A, Mortezavi A, Nagel
H, Kranzbühler B, Eberli D, Burger IA. The central zone has increased
(68)Ga-PSMA-11 uptake: "Mickey Mouse ears" can be hot on (68)Ga-PSMA-11 PET. Eur 
J Nucl Med Mol Imaging. 2018 Jul;45(8):1335-1343. doi: 10.1007/s00259-018-3979-2.
Epub 2018 Mar 9. PubMed PMID: 29523924.


162: Klein Nulent TJW, Valstar MH, de Keizer B, Willems SM, Smit LA, Al-Mamgani
A, Smeele LE, van Es RJJ, de Bree R, Vogel WV. Physiologic distribution of
PSMA-ligand in salivary glands and seromucous glands of the head and neck on
PET/CT. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May;125(5):478-486. doi:
10.1016/j.oooo.2018.01.011. Epub 2018 Jan 31. PubMed PMID: 29523427.


163: Ceci F, Castellucci P, Fanti S. Current application and future perspectives 
of prostate specific membrane antigen PET imaging in prostate cancer. Q J Nucl
Med Mol Imaging. 2019 Mar;63(1):7-18. doi: 10.23736/S1824-4785.18.03059-5. Epub
2018 Mar 8. Review. PubMed PMID: 29521482.


164: Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C,
Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C. Outcome after PSMA 
PET/CT based radiotherapy in patients with biochemical persistence or recurrence 
after radical prostatectomy. Radiat Oncol. 2018 Mar 2;13(1):37. doi:
10.1186/s13014-018-0983-4. PubMed PMID: 29499730; PubMed Central PMCID:
PMC5833127.


165: Afshar-Oromieh A, Sattler LP, Steiger K, Holland-Letz T, da Cunha ML, Mier
W, Neels O, Kopka K, Weichert W, Haberkorn U. Tracer uptake in mediastinal and
paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of
PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1179-1187. doi:
10.1007/s00259-018-3965-8. Epub 2018 Mar 1. PubMed PMID: 29497802.


166: Schiller K, Devecka M, Maurer T, Eiber M, Gschwend J, Schwaiger M, Combs SE,
Habl G. Impact of (68)Ga-PSMA-PET imaging on target volume definition and
guidelines in radiation oncology - a patterns of failure analysis in patients
with primary diagnosis of prostate cancer. Radiat Oncol. 2018 Mar 1;13(1):36.
doi: 10.1186/s13014-018-0977-2. PubMed PMID: 29490670; PubMed Central PMCID:
PMC5831712.


167: Beheshti M, Paymani Z, Brilhante J, Geinitz H, Gehring D, Leopoldseder T,
Wouters L, Pirich C, Loidl W, Langsteger W. Optimal time-point for (68)Ga-PSMA-11
PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit 
tracer preparation? Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1188-1196. doi:
10.1007/s00259-018-3970-y. Epub 2018 Feb 23. PubMed PMID: 29476228.


168: Parida GK, Tripathy S, Datta Gupta S, Singhal A, Kumar R, Bal C, Shamim SA. 
Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of
18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. Clin Nucl Med. 2018
Apr;43(4):248-249. doi: 10.1097/RLU.0000000000002013. PubMed PMID: 29474196.


169: Vadi SK, Kumar R, Mittal BR, Singh H, Singh SK. 68Ga-PSMA PET/CT Revealing
Unusual Inguinal Canal and Distant Nodal Metastasis in a Case of
Castration-Resistant Prostate Cancer. Clin Nucl Med. 2018 Apr;43(4):279-281. doi:
10.1097/RLU.0000000000002002. PubMed PMID: 29465494.


170: Vadi SK, Kumar R, Mittal BR, Parihar AS, Singh SK. Unusual Case of Diffuse
Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA
Posttherapy Scintigraphy. Clin Nucl Med. 2018 Apr;43(4):276-278. doi:
10.1097/RLU.0000000000002001. PubMed PMID: 29465493.


171: Chaussé G, Abikhzer G, Probst S. Small Lymph Node Metastasis Detected by
68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in
Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer. Clin
Nucl Med. 2018 Apr;43(4):250-251. doi: 10.1097/RLU.0000000000002009. PubMed PMID:
29465489.


172: Bouchelouche K, Choyke PL. Advances in prostate-specific membrane antigen
PET of prostate cancer. Curr Opin Oncol. 2018 May;30(3):189-196. doi:
10.1097/CCO.0000000000000439. Review. PubMed PMID: 29465429; PubMed Central
PMCID: PMC6003670.


173: Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking
T, Keyver-Paik MD, Kaiser C, Ahmadzadehfar H, Essler M, Kuhn W, Kristiansen G.
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation
of expression and a case report of radionuclide therapy. Breast Cancer Res Treat.
2018 Jun;169(3):447-455. doi: 10.1007/s10549-018-4717-y. Epub 2018 Feb 17. PubMed
PMID: 29455299.


174: Medina-Ornelas Sevastián S, García-Pérez Francisco O, Hernández-Pedro Norma 
Y, Arellano-Zarate Angélica E, Abúndiz-López Blanca L. Correlation between
molecular tumor volume evaluated with (68)Ga-PSMA PET/CT and prostatic specific
antigen levels. Rev Esp Med Nucl Imagen Mol. 2018 Jul - Aug;37(4):223-228. doi:
10.1016/j.remn.2017.10.005. Epub 2018 Feb 14. English, Spanish. PubMed PMID:
29454548.


175: Cuccurullo V, di Stasio GD, Evangelista L, Ciarmiello A, Mansi L. Will
(68)Ga PSMA-radioligands be the only choice for nuclear medicine in prostate
cancer in the near future? A clinical update. Rev Esp Med Nucl Imagen Mol. 2018
Mar - Apr;37(2):103-109. doi: 10.1016/j.remn.2017.10.008. Epub 2018 Feb 13.
Review. English, Spanish. PubMed PMID: 29422356.


176: Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC,
Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.
Biochemical Recurrence of Prostate Cancer: Initial Results with [(18)F]PSMA-1007 
PET/CT. J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 
2018 Feb 1. PubMed PMID: 29419475.


177: Dias AH, Bouchelouche K. Prostate-Specific Membrane Antigen PET/CT
Incidental Finding of a Schwannoma. Clin Nucl Med. 2018 Apr;43(4):267-268. doi:
10.1097/RLU.0000000000001988. PubMed PMID: 29401152.


178: Al-Bayati M, Grueneisen J, Lütje S, Sawicki LM, Suntharalingam S,
Tschirdewahn S, Forsting M, Rübben H, Herrmann K, Umutlu L, Wetter A. Integrated 
68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission
Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of
Multi-Parametric Prostate Magnetic Resonance Imaging. Urol Int.
2018;100(2):164-171. doi: 10.1159/000484695. Epub 2018 Jan 25. PubMed PMID:
29393268.


179: Evangelista L, Cuppari L, Zattoni F, Mansi L, Bombardieri E. The future of
choline PET in the era of prostate specific membrane antigen. Q J Nucl Med Mol
Imaging. 2019 Mar;63(1):19-28. doi: 10.23736/S1824-4785.18.03062-5. Epub 2018 Jan
30. Review. PubMed PMID: 29383928.


180: Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M,
Gschwend J, Maurer T, Meyer PT, Eiber M. (68)Ga-PSMA-HBED-CC Uptake in Cervical, 
Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET
Imaging. J Nucl Med. 2018 Sep;59(9):1406-1411. doi: 10.2967/jnumed.117.204677.
Epub 2018 Jan 25. PubMed PMID: 29371407.


181: Rutledge AB, McLeod N, Mehan N, Regan TW, Ainsworth P, Chong P, Doyle T,
White M, Sanson-Fisher RW, Martin JM. A clinician-centred programme for behaviour
change in the optimal use of staging investigations for newly diagnosed prostate 
cancer. BJU Int. 2018 May;121 Suppl 3:22-27. doi: 10.1111/bju.14144. Epub 2018
Feb 16. PubMed PMID: 29359883.


182: Corfield J, Perera M, Bolton D, Lawrentschuk N. (68)Ga-prostate specific
membrane antigen (PSMA) positron emission tomography (PET) for primary staging of
high-risk prostate cancer: a systematic review. World J Urol. 2018
Apr;36(4):519-527. doi: 10.1007/s00345-018-2182-1. Epub 2018 Jan 17. Review.
PubMed PMID: 29344682.


183: Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bögemann M, Stegger L, 
Weckesser M, Schäfers M, Rahbar K. Targeting PSMA by radioligands in non-prostate
disease-current status and future perspectives. Eur J Nucl Med Mol Imaging. 2018 
May;45(5):860-877. doi: 10.1007/s00259-017-3922-y. Epub 2018 Jan 15. Review.
PubMed PMID: 29335762.


184: Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL,
Haberkorn U, Morgenstern A. Targeted α-Therapy of Metastatic Castration-Resistant
Prostate Cancer with (225)Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy
Regarding Duration of Tumor Control. J Nucl Med. 2018 May;59(5):795-802. doi:
10.2967/jnumed.117.203539. Epub 2018 Jan 11. PubMed PMID: 29326358.


185: Gupta M, Choudhury PS, Rawal S, Goel HC, Singh A, Talwar V, Sahoo SK. Risk
stratification and staging in prostate cancer with prostatic specific membrane
antigen PET/CTObjective: A one-stop-shop. Hell J Nucl Med. 2017 Sep-Dec;20
Suppl:156. PubMed PMID: 29324926.


186: Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen
PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. 
Radiographics. 2018 Jan-Feb;38(1):200-217. doi: 10.1148/rg.2018170108. Review.
PubMed PMID: 29320333.


187: Calais J, Cao M, Nickols NG. The Utility of PET/CT in the Planning of
External Radiation Therapy for Prostate Cancer. J Nucl Med. 2018
Apr;59(4):557-567. doi: 10.2967/jnumed.117.196444. Epub 2018 Jan 4. PubMed PMID: 
29301928.


188: Anconina R, Hod N, Levin D, Ezroh Kazap D, Lantsberg S. Incidental Detection
of Metastatic Malignant Melanoma on 68Ga-Prostate-Specific Membrane Antigen
PET/CT Imaging: Correlative Imaging With FDG PET/CT and Review of the Literature.
Clin Nucl Med. 2018 Mar;43(3):204-206. doi: 10.1097/RLU.0000000000001959. PubMed 
PMID: 29293137.


189: Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of
theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018
Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28. Review.
PubMed PMID: 29282518; PubMed Central PMCID: PMC5787224.


190: Gupta SK, Watson T, Denham J, Shakespeare TP, Rutherford N, McLeod N, Picton
K, Ainsworth P, Bonaventura T, Martin JM. Prostate-Specific Membrane Antigen
Positron Emission Tomography-Computed Tomography for Prostate Cancer:
Distribution of Disease and Implications for Radiation Therapy Planning. Int J
Radiat Oncol Biol Phys. 2017 Nov 1;99(3):701-709. doi:
10.1016/j.ijrobp.2017.06.2448. Epub 2017 Jun 27. PubMed PMID: 29280465.


191: Giesel FL, Will L, Paddubny K, Kremer C, Rathke H, Radtke JP, Kopka K, Haufe
S, Haberkorn U, Kratochwil C. [18F]PSMA-1007 PET Improves the Diagnosis of Local 
Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History 
of Bilateral Hip Arthroplasty. Clin Genitourin Cancer. 2018 Apr;16(2):111-113.
doi: 10.1016/j.clgc.2017.11.008. Epub 2017 Dec 6. PubMed PMID: 29276131.


192: Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O,
Reyneke F, Haberkon U, Kopka K, Sathekge M. Intraindividual Comparison of
(18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the Prospective Evaluation of Patients
with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med. 2018
Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21. PubMed
PMID: 29269569.


193: Iravani A, Hofman MS, Mulcahy T, Williams S, Murphy D, Parameswaran BK,
Hicks RJ. (68)Ga PSMA-11 PET with CT urography protocol in the initial staging
and biochemical relapse of prostate cancer. Cancer Imaging. 2017 Dec 21;17(1):31.
doi: 10.1186/s40644-017-0133-5. PubMed PMID: 29268784; PubMed Central PMCID:
PMC5740783.


194: Will L, Giesel FL, Freitag MT, Berger AK, Mier W, Kopka K, Koerber SA,
Rathke H, Kremer C, Kratochwil C, Kauczor HU, Haberkorn U, Weber TF. Integration 
of CT urography improves diagnostic confidence of (68)Ga-PSMA-11 PET/CT in
prostate cancer patients. Cancer Imaging. 2017 Dec 20;17(1):30. doi:
10.1186/s40644-017-0132-6. PubMed PMID: 29262870; PubMed Central PMCID:
PMC5738706.


195: Broos WAM, Kocken M, van der Zant FM, Knol RJJ, Wondergem M. Metastasized
18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine
Differentiation. Clin Nucl Med. 2018 Feb;43(2):120-122. doi:
10.1097/RLU.0000000000001929. PubMed PMID: 29261618.


196: von Klot CJ, Merseburger AS, Böker A, Schmuck S, Ross TL, Bengel FM, Kuczyk 
MA, Henkenberens C, Christiansen H, Wester HJ, Solass W, Lafos M, Derlin T.
(68)Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular 
Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients
with Prostate Cancer. Nucl Med Mol Imaging. 2017 Dec;51(4):314-322. doi:
10.1007/s13139-017-0476-7. Epub 2017 Mar 7. PubMed PMID: 29242725; PubMed Central
PMCID: PMC5721087.


197: Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Comparison of
(68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with
Prostate Cancer Recurrence. J Nucl Med. 2018 May;59(5):789-794. doi:
10.2967/jnumed.117.203257. Epub 2017 Dec 14. PubMed PMID: 29242404.


198: Hammes J, Täger P, Drzezga A. EBONI: A Tool for Automated Quantification of 
Bone Metastasis Load in PSMA PET/CT. J Nucl Med. 2018 Jul;59(7):1070-1075. doi:
10.2967/jnumed.117.203265. Epub 2017 Dec 14. PubMed PMID: 29242401.


199: Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar
M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer.
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):4-21. doi:
10.1038/s41391-017-0007-8. Epub 2017 Dec 11. Review. PubMed PMID: 29230009.


200: Udovicich C, Perera M, Hofman MS, Siva S, Del Rio A, Murphy DG, Lawrentschuk
N. (68)Ga-prostate-specific membrane antigen-positron emission
tomography/computed tomography in advanced prostate cancer: Current state and
future trends. Prostate Int. 2017 Dec;5(4):125-129. doi:
10.1016/j.prnil.2017.02.003. Epub 2017 Feb 24. Review. PubMed PMID: 29188197;
PubMed Central PMCID: PMC5693469.


201: Baumann R, Koncz M, Luetzen U, Krause F, Dunst J. Oligometastases in
prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after
hypofractionated IGRT. Strahlenther Onkol. 2018 Apr;194(4):318-324. doi:
10.1007/s00066-017-1239-1. Epub 2017 Nov 27. PubMed PMID: 29181556; PubMed
Central PMCID: PMC5869895.


202: Laurens ST, Witjes F, Janssen M, Flucke U, Gottardt M.
68Ga-Prostate-Specific Membrane Antigen Uptake in Gastrointestinal Stromal Tumor.
Clin Nucl Med. 2018 Jan;43(1):60-61. doi: 10.1097/RLU.0000000000001902. PubMed
PMID: 29166327.


203: Herlemann A, Kretschmer A, Buchner A, Karl A, Tritschler S, El-Malazi L,
Fendler WP, Wenter V, Ilhan H, Bartenstein P, Stief CG, Gratzke C. Salvage lymph 
node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in
prostate cancer patients. Oncotarget. 2017 Sep 21;8(48):84180-84192. doi:
10.18632/oncotarget.21118. eCollection 2017 Oct 13. PubMed PMID: 29137414; PubMed
Central PMCID: PMC5663586.


204: Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk
MA, Christiansen H, von Klot CA. Patterns of relapse as determined by (68)Ga-PSMA
ligand PET/CT after radical prostatectomy : Importance for tailoring and
individualizing treatment. Strahlenther Onkol. 2018 Apr;194(4):303-310. doi:
10.1007/s00066-017-1231-9. Epub 2017 Nov 13. PubMed PMID: 29134231.


205: Byrne K, Eade T, Kneebone A, Guo L, Hsiao E, Schembri G, Kwong C, Hunter J, 
Emmett L, Hruby G. Delineating sites of failure following post-prostatectomy
radiation treatment using (68)Ga-PSMA-PET. Radiother Oncol. 2018
Feb;126(2):244-248. doi: 10.1016/j.radonc.2017.10.022. Epub 2017 Nov 10. PubMed
PMID: 29132644.


206: Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M,
Eze C, Li M, Bartenstein P, Belka C, Ganswindt U. Detection level and pattern of 
positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiat
Oncol. 2017 Nov 10;12(1):176. doi: 10.1186/s13014-017-0902-0. PubMed PMID:
29126446; PubMed Central PMCID: PMC5681820.


207: Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T,
Reiter R, Maurer T, Weber WA, Fendler WP. Prostate Cancer Molecular Imaging
Standardized Evaluation (PROMISE): Proposed miTNM Classification for the
Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018 Mar;59(3):469-478. doi:
10.2967/jnumed.117.198119. Epub 2017 Nov 9. Erratum in: J Nucl Med. 2018
Jun;59(6):992. PubMed PMID: 29123012.


208: Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H.
Reconsidering the role of pelvic lymph node dissection with radical prostatectomy
for prostate cancer in an era of improving radiological staging techniques. World
J Urol. 2018 Jan;36(1):15-20. doi: 10.1007/s00345-017-2119-0. Epub 2017 Nov 7.
PubMed PMID: 29116393.


209: Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao 
X, Wang W, Wang F, Guo H. Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for
preoperative lymph node staging in patients with intermediate to high-risk
prostate cancer. J Transl Med. 2017 Nov 7;15(1):230. doi:
10.1186/s12967-017-1333-2. PubMed PMID: 29115970; PubMed Central PMCID:
PMC5688809.


210: Chaloupka M, Herlemann A, D'Anastasi M, Cyran CC, Ilhan H, Gratzke C, Stief 
CG. (68)Gallium-Prostate-Specific Membrane Antigen PET/Computed Tomography for
Primary and Secondary Staging in Prostate Cancer. Urol Clin North Am. 2017
Nov;44(4):557-563. doi: 10.1016/j.ucl.2017.07.004. Review. PubMed PMID: 29107272.


211: Zarzour JG, Galgano S, McConathy J, Thomas JV, Rais-Bahrami S. Lymph node
imaging in initial staging of prostate cancer: An overview and update. World J
Radiol. 2017 Oct 28;9(10):389-399. doi: 10.4329/wjr.v9.i10.389. Review. PubMed
PMID: 29104741; PubMed Central PMCID: PMC5661167.


212: Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawal I, Ebenhan T,
Van de Wiele C. (68)Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma:
preliminary results on differences between black and white South-Africans. Eur J 
Nucl Med Mol Imaging. 2018 Feb;45(2):226-234. doi: 10.1007/s00259-017-3852-8.
Epub 2017 Nov 4. PubMed PMID: 29101444; PubMed Central PMCID: PMC5745572.


213: Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. PET/CT With
(68)Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical
Implications. Curr Radiopharm. 2018;11(1):4-13. doi:
10.2174/1874471010666171101121803. Review. PubMed PMID: 29090673.


214: Zacho HD, Nielsen JB, Haberkorn U, Stenholt L, Petersen LJ. (68) Ga-PSMA
PET/CT for the detection of bone metastases in prostate cancer: a systematic
review of the published literature. Clin Physiol Funct Imaging. 2017 Oct 29. doi:
10.1111/cpf.12480. [Epub ahead of print] PubMed PMID: 29082604.


215: Strele-Trieb P, Dunzinger A, Sonnberger M, Wolfsgruber J, Pichler R. Uptake 
of 68Ga-Prostate-Specific Membrane Antigen PET in Adrenal Gland: A Potential
Pitfall. Clin Nucl Med. 2018 Jan;43(1):50-51. doi: 10.1097/RLU.0000000000001881. 
PubMed PMID: 29076912.


216: Demirci E, Has Simsek D, Kabasakal L, Mülazimoğlu M. Abdominal Splenosis
Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT,
Confirmed With Selective Spleen SPECT/CT. Clin Nucl Med. 2017
Dec;42(12):e504-e505. doi: 10.1097/RLU.0000000000001878. PubMed PMID: 29076911.


217: Jochumsen MR, Dias AH, Bouchelouche K. Benign Traumatic Rib Fracture: A
Potential Pitfall on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Prostate 
Cancer. Clin Nucl Med. 2018 Jan;43(1):38-40. doi: 10.1097/RLU.0000000000001871.
PubMed PMID: 29076907.


218: Zaman MU, Fatima N, Zaman A, Sajid M, Zaman U, Zaman S. Diagnostic
Challenges in Prostate Cancer and 68Ga-PSMA PET Imaging: A Game Changer? Asian
Pac J Cancer Prev. 2017 Oct 26;18(10):2625-2628. PubMed PMID: 29072055; PubMed
Central PMCID: PMC5747380.


219: Nawaz S, Mullen GED, Sunassee K, Bordoloi J, Blower PJ, Ballinger JR.
Simple, mild, one-step labelling of proteins with gallium-68 using a
tris(hydroxypyridinone) bifunctional chelator: a (68)Ga-THP-scFv targeting the
prostate-specific membrane antigen. EJNMMI Res. 2017 Oct 25;7(1):86. doi:
10.1186/s13550-017-0336-6. PubMed PMID: 29067565; PubMed Central PMCID:
PMC5655379.


220: Meißner S, Janssen JC, Prasad V, Brenner W, Diederichs G, Hamm B, Hofheinz
F, Makowski MR. Potential of asphericity as a novel diagnostic parameter in the
evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer
lesions. EJNMMI Res. 2017 Oct 23;7(1):85. doi: 10.1186/s13550-017-0333-9. PubMed 
PMID: 29058157; PubMed Central PMCID: PMC5651532.


221: Freitag MT, Kesch C, Cardinale J, Flechsig P, Floca R, Eiber M, Bonekamp D, 
Radtke JP, Kratochwil C, Kopka K, Hohenfellner M, Stenzinger A, Schlemmer HP,
Haberkorn U, Giesel F. Simultaneous whole-body (18)F-PSMA-1007-PET/MRI with
integrated high-resolution multiparametric imaging of the prostatic fossa for
comprehensive oncological staging of patients with prostate cancer: a pilot
study. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):340-347. doi:
10.1007/s00259-017-3854-6. Epub 2017 Oct 16. PubMed PMID: 29038888.


222: Kranzbühler B, Nagel H, Becker AS, Müller J, Huellner M, Stolzmann P,
Muehlematter U, Guckenberger M, Kaufmann PA, Eberli D, Burger IA. Clinical
performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate
cancer following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2018
Jan;45(1):20-30. doi: 10.1007/s00259-017-3850-x. Epub 2017 Oct 14. PubMed PMID:
29032394.


223: Maurer T, Gschwend JE, Eiber M. Prostate-specific membrane antigen-guided
salvage lymph node dissection in recurrent prostate cancer: a novel technology to
detect lymph node metastases. Curr Opin Urol. 2018 Mar;28(2):191-196. doi:
10.1097/MOU.0000000000000458. Review. PubMed PMID: 29028767.


224: Horn T, Rauscher I, Eiber M, Gschwend JE, Maurer T. [PSMA-radioguided
surgery in localised recurrent prostate cancer]. Urologe A. 2017
Nov;56(11):1417-1423. doi: 10.1007/s00120-017-0516-z. Review. German. PubMed
PMID: 29022058.


225: von Hardenberg J, Büsing KA, Nuhn P, Ritter M. [The role of PSMA PET-CT in
patients with metastatic prostate cancer]. Urologe A. 2017 Nov;56(11):1410-1416. 
doi: 10.1007/s00120-017-0513-2. Review. German. PubMed PMID: 28980045.


226: Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C. Comparison of
68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate
cancer68Ga-PSMA PET and MRI in prostate cancer. Nucl Med Commun. 2017
Dec;38(12):1094-1102. doi: 10.1097/MNM.0000000000000749. PubMed PMID: 28957842.


227: García Garzón JR, de Arcocha Torres M, Delgado-Bolton R, Ceci F, Alvarez
Ruiz S, Orcajo Rincón J, Caresia Aróztegui AP, García Velloso MJ, García Vicente 
AM; Oncology Task Force of Spanish Society of Nuclear Medicine and Molecular
Imaging. (68)Ga-PSMA PET/CT in prostate cancer. Rev Esp Med Nucl Imagen Mol. 2018
Mar - Apr;37(2):130-138. doi: 10.1016/j.remn.2017.07.004. Epub 2017 Sep 21.
Review. English, Spanish. PubMed PMID: 28941866.


228: Dam JH, Olsen BB, Baun C, Høilund-Carlsen PF, Thisgaard H. A PSMA Ligand
Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Mol Imaging Biol. 2017
Dec;19(6):915-922. doi: 10.1007/s11307-017-1121-7. PubMed PMID: 28924629.


229: Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A. The role of
68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Nucl
Med Commun. 2017 Nov;38(11):956-963. doi: 10.1097/MNM.0000000000000738. PubMed
PMID: 28922335.


230: Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E,
Ozluk Y, Yildiz SO, Turkmen C. Relationships between serum PSA levels, Gleason
scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Ann Nucl Med. 2017 Nov;31(9):709-717. doi: 10.1007/s12149-017-1207-y. Epub 2017
Sep 12. PubMed PMID: 28900854.


231: Bailey J, Piert M. Performance of (68)Ga-PSMA PET/CT for Prostate Cancer
Management at Initial Staging and Time of Biochemical Recurrence. Curr Urol Rep. 
2017 Sep 9;18(11):84. doi: 10.1007/s11934-017-0736-1. Review. PubMed PMID:
28889366.


232: Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW. Influence of Androgen
Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities
and Challenges. Nucl Med Mol Imaging. 2017 Sep;51(3):202-211. doi:
10.1007/s13139-016-0439-4. Epub 2016 Aug 6. Review. PubMed PMID: 28878845; PubMed
Central PMCID: PMC5567615.


233: Joice GA, Rowe SP, Pienta KJ, Gorin MA. Oligometastatic prostate cancer:
shaping the definition with molecular imaging and an improved understanding of
tumor biology. Curr Opin Urol. 2017 Nov;27(6):533-541. doi:
10.1097/MOU.0000000000000449. Review. PubMed PMID: 28863016.


234: Cornelis FH, Durack JC, Pandit-Taskar N, Ulaner GA, Lewis JS, Morris MJ,
Solomon SB. Long-Half-Life (89)Zr-Labeled Radiotracers Can Guide Percutaneous
Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. J Nucl Med.
2018 Mar;59(3):399-402. doi: 10.2967/jnumed.117.194480. Epub 2017 Aug 17. PubMed 
PMID: 28818992; PubMed Central PMCID: PMC5868497.


235: Turkbey B, Mena E, Lindenberg L, Adler S, Bednarova S, Berman R, Ton AT,
McKinney Y, Eclarinal P, Hill C, Afari G, Bhattacharyya S, Mease RC, Merino MJ,
Jacobs PM, Wood BJ, Pinto PA, Pomper MG, Choyke PL. 18F-DCFBC Prostate-Specific
Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer:
Correlation With Multiparametric MRI and Histopathology. Clin Nucl Med. 2017
Oct;42(10):735-740. doi: 10.1097/RLU.0000000000001804. PubMed PMID: 28806263;
PubMed Central PMCID: PMC5703072.


236: Hammes J, Kobe C, Hilgenberg U, Lieb WE, Drzezga A. Orbital
Hemangiopericytoma in 68Ga-Prostate-Specific Membrane Antigen-HBED-CC PET/CT.
Clin Nucl Med. 2017 Oct;42(10):812-814. doi: 10.1097/RLU.0000000000001791. PubMed
PMID: 28806257.


237: Alipour R, Gupta S, Trethewey S. 68Ga-PSMA Uptake in Combined Hepatocellular
Cholangiocarcinoma With Skeletal Metastases. Clin Nucl Med. 2017
Oct;42(10):e452-e453. doi: 10.1097/RLU.0000000000001771. PubMed PMID: 28806238.


238: Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, de
Ridder M. The feasibility of prostate-specific membrane antigen positron emission
tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer
patients. Clin Transl Oncol. 2018 Apr;20(4):484-490. doi:
10.1007/s12094-017-1736-9. Epub 2017 Aug 9. PubMed PMID: 28795303.


239: Bandini M, Fossati N, Briganti A. Salvage surgery for nodal recurrent
prostate cancer. Curr Opin Urol. 2017 Nov;27(6):604-611. doi:
10.1097/MOU.0000000000000437. Review. PubMed PMID: 28787319.


240: Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B,
Makowski MR. Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for
the detection of bone metastases in prostate cancer patients: Additional value of
morphologic information from low dose CT. Eur Radiol. 2018 Feb;28(2):610-619.
doi: 10.1007/s00330-017-4994-6. Epub 2017 Aug 4. PubMed PMID: 28779400.


241: Sahbai S, Rieping P, Pfannenberg C, la Fougére C, Reimold M. Pancreatic
Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific
Membrane Antigen PET/CT. Clin Nucl Med. 2017 Sep;42(9):717-718. doi:
10.1097/RLU.0000000000001767. PubMed PMID: 28777194.


242: Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K,
Makowski MR, Brenner W, Prasad V. Immunohistochemical Validation of PSMA
Expression Measured by (68)Ga-PSMA PET/CT in Primary Prostate Cancer. J Nucl Med.
2018 Feb;59(2):238-243. doi: 10.2967/jnumed.117.195172. Epub 2017 Aug 3. PubMed
PMID: 28775203.


243: Sathianathen NJ, Geurts N, Nair R, Lawrentschuk N, Murphy DG, Lamb AD. The
phytological future of prostate cancer staging: PSMA-PET and the dandelion
theory. Future Oncol. 2017 Aug;13(20):1801-1807. doi: 10.2217/fon-2017-0074. Epub
2017 Aug 1. Review. PubMed PMID: 28762288.


244: von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. (68)Ga-Labeled
Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed
Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol
Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
PubMed PMID: 28753806.


245: Tuncel M, Telli T. Value of post-therapy (177)Lu-PSMA images for accurate
interpretation of therapy response with (68)Ga-PSMA PET/CT. Rev Esp Med Nucl
Imagen Mol. 2018 Mar - Apr;37(2):114-117. doi: 10.1016/j.remn.2017.05.004. Epub
2017 Jul 24. English, Spanish. PubMed PMID: 28750750.


246: Petersen LJ, Zacho HD. Gallium-68 prostate-specific membrane antigen
positron emission tomography/computed tomography for staging of high-risk
prostate cancer. Scand J Urol. 2017 Dec;51(6):498-501. doi:
10.1080/21681805.2017.1354913. Epub 2017 Jul 27. Review. PubMed PMID: 28748722.


247: Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross 
AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM,
Pomper MG, Allaf ME. Prostate Specific Membrane Antigen Targeted (18)F-DCFPyL
Positron Emission Tomography/Computerized Tomography for the Preoperative Staging
of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center
Study. J Urol. 2018 Jan;199(1):126-132. doi: 10.1016/j.juro.2017.07.070. Epub
2017 Jul 20. PubMed PMID: 28736318; PubMed Central PMCID: PMC5802365.


248: Bednarova S, Lindenberg ML, Vinsensia M, Zuiani C, Choyke PL, Turkbey B.
Positron emission tomography (PET) in primary prostate cancer staging and risk
assessment. Transl Androl Urol. 2017 Jun;6(3):413-423. doi:
10.21037/tau.2017.03.53. Review. PubMed PMID: 28725583; PubMed Central PMCID:
PMC5503952.


249: Knorr K, Eiber M, Maurer T, Wester HJ, Scheidhauer K. [PET-CT and PET-MRI of
the prostate : From (18)F-FDG to (68)Ga-PSMA]. Radiologe. 2017 Aug;57(8):631-636.
doi: 10.1007/s00117-017-0276-1. Review. German. PubMed PMID: 28688023.


250: Gupta M, Choudhury PS, Hazarika D, Rawal S. A Comparative Study of
(68)Gallium-Prostate Specific Membrane Antigen Positron Emission
Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node
Staging in High Risk Prostate Cancer Patients: An Initial Experience. World J
Nucl Med. 2017 Jul-Sep;16(3):186-191. doi: 10.4103/1450-1147.207272. PubMed PMID:
28670175; PubMed Central PMCID: PMC5460300.


251: Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, Combs SE, Habl
G. Patterns of failure after radical prostatectomy in prostate cancer -
implications for radiation therapy planning after (68)Ga-PSMA-PET imaging. Eur J 
Nucl Med Mol Imaging. 2017 Sep;44(10):1656-1662. doi: 10.1007/s00259-017-3746-9. 
Epub 2017 Jun 23. PubMed PMID: 28646463.


252: Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen 
QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM. The
Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of 
an Australian Prospective Multicenter Study. J Nucl Med. 2018 Jan;59(1):82-88.
doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23. PubMed PMID: 28646014.


253: Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K,
Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M,
Giesel FL. (68)Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph
Nodes Stratified by Tumor Differentiation of Prostate Cancer. J Nucl Med. 2017
Dec;58(12):1949-1955. doi: 10.2967/jnumed.116.185033. Epub 2017 Jun 21. PubMed
PMID: 28637799.


254: Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ. New advances in focal
therapy for early stage prostate cancer. Expert Rev Anticancer Ther. 2017
Aug;17(8):737-743. doi: 10.1080/14737140.2017.1345630. Epub 2017 Jun 28. Review. 
PubMed PMID: 28635336.


255: Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, Yücetaş U,
Demirdağ Ç, Erdoğan SM, Kabasakal L; Members of Urooncology Association, Turkey. 
The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk
prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1806-1812. doi:
10.1007/s00259-017-3752-y. Epub 2017 Jun 18. PubMed PMID: 28624849.


256: Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, Emmett L. Frusemide 
aids diagnostic interpretation of (68) Ga-PSMA positron emission tomography/CT in
men with prostate cancer. J Med Imaging Radiat Oncol. 2017 Dec;61(6):739-744.
doi: 10.1111/1754-9485.12625. Epub 2017 Jun 17. PubMed PMID: 28623852.


257: Bates A, Miles K. Prostate-specific membrane antigen PET/MRI validation of
MR textural analysis for detection of transition zone prostate cancer. Eur
Radiol. 2017 Dec;27(12):5290-5298. doi: 10.1007/s00330-017-4877-x. Epub 2017 Jun 
12. PubMed PMID: 28608163.


258: Kranzbühler B, Tran S, Zilli T, Burger IA. 68Ga-PSMA PET/MR-Positive
Peritoneal Metastasis in the Falciform Ligament in Recurrent Prostate Cancer.
Clin Nucl Med. 2017 Aug;42(8):e388-e389. doi: 10.1097/RLU.0000000000001703.
PubMed PMID: 28590295.


259: Uprimny C. (68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in
prostate cancer imaging? Wien Med Wochenschr. 2019 Feb;169(1-2):3-11. doi:
10.1007/s10354-017-0569-z. Epub 2017 Jun 2. Review. PubMed PMID: 28577076.


260: Bieth M, Krönke M, Tauber R, Dahlbender M, Retz M, Nekolla SG, Menze B,
Maurer T, Eiber M, Schwaiger M. Exploring New Multimodal Quantitative Imaging
Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using
(68)Ga-PSMA PET/CT. J Nucl Med. 2017 Oct;58(10):1632-1637. doi:
10.2967/jnumed.116.189050. Epub 2017 May 25. PubMed PMID: 28546330.


261: Ceci F, Herrmann K, Hadaschik B, Castellucci P, Fanti S. Therapy assessment 
in prostate cancer using choline and PSMA PET/CT. Eur J Nucl Med Mol Imaging.
2017 Aug;44(Suppl 1):78-83. doi: 10.1007/s00259-017-3723-3. Epub 2017 May 25.
Review. PubMed PMID: 28540419.


262: Kallur KG, Ramachandra PG, Rajkumar K, Swamy SS, Desai I, Rao RM, Patil SG, 
Sridhar PS, Madhusudhan N, Krishnappa RS, Bhadrasetty V, Kumara HM, Santhosh SD, 
Ajaikumar BS. Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate
Cancer. Indian J Nucl Med. 2017 Apr-Jun;32(2):110-117. doi:
10.4103/0972-3919.202255. PubMed PMID: 28533638; PubMed Central PMCID:
PMC5439210.


263: Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U,
Schultze-Seemann W, Meyer PT. Diagnostic Accuracy of
Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for
Recurrent Prostate Cancer. Theranostics. 2017 Apr 10;7(6):1770-1780. doi:
10.7150/thno.18421. eCollection 2017. PubMed PMID: 28529650; PubMed Central
PMCID: PMC5436526.


264: Rauscher I, Eiber M, Maurer T. [PSMA-Radioguided Surgery for Salvage
Lymphadenectomy in Recurrent Prostate Cancer]. Aktuelle Urol. 2017
Apr;48(2):148-152. doi: 10.1055/s-0042-120455. Epub 2017 May 16. German. PubMed
PMID: 28511221.


265: Gasch C, Körber S, Kremer C, Eiber M, Kratochwil C, Haberkorn U,
Hohenfellner M, Hadaschik B, Giesel FL. [Significance and Value of PSMA Ligands
in Prostate Cancer]. Aktuelle Urol. 2017 Apr;48(2):140-147. doi:
10.1055/s-0043-100269. Epub 2017 May 16. Review. German. PubMed PMID: 28511220.


266: Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, 
Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor
HU, Debus J, Haberkorn U. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC)
PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi:
10.1007/s00259-017-3711-7. Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol
Imaging. 2017 Sep;44(10 ):1781. PubMed PMID: 28497198; PubMed Central PMCID:
PMC5486817.


267: Roy SG, Parida GK, Tripathy S, Singhal A, Tripathi M, Bal C. In Vivo
Demonstration of PSMA Expression in Adenocarcinoma Urinary Bladder Using
68Ga-PSMA 11 PET/CT. Clin Nucl Med. 2017 Jul;42(7):542-543. doi:
10.1097/RLU.0000000000001683. PubMed PMID: 28481793.


268: Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J,
Rabenalt R, Antoch G, Buchbender C. Evaluation of Practical Interpretation
Hurdles in 68Ga-PSMA PET/CT in 55 Patients: Physiological Tracer Distribution and
Incidental Tracer Uptake. Clin Nucl Med. 2017 Jul;42(7):e322-e327. doi:
10.1097/RLU.0000000000001672. PubMed PMID: 28481787.


269: Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E,
Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M,
Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U,
Hadaschik BA, Giesel FL. Intraindividual Comparison of (18)F-PSMA-1007 PET/CT,
Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary
Prostate Cancer: A Retrospective, Proof-of-Concept Study. J Nucl Med. 2017
Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4. Erratum
in: J Nucl Med. 2019 Apr;60(4):554. PubMed PMID: 28473595.


270: Bandini M, Gandaglia G, Fossati N, Montorsi F, Briganti A. An Explanatory
Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. Urol 
Case Rep. 2017 Mar 10;12:34-36. doi: 10.1016/j.eucr.2017.02.011. eCollection 2017
May. PubMed PMID: 28462154; PubMed Central PMCID: PMC5408758.


271: Witkowska-Patena E, Mazurek A, Dziuk M. 68Ga-PSMA PET/CT imaging in
recurrent prostate cancer: Where are we now? Cent European J Urol.
2017;70(1):37-43. doi: 10.5173/ceju.2017.947. Epub 2017 Jan 11. Review. PubMed
PMID: 28461986; PubMed Central PMCID: PMC5407340.


272: Wondergem M, van der Zant FM, Knol RJJ, Lazarenko SV, Pruim J, de Jong IJ.
(18)F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes:
Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. J Nucl
Med. 2017 Nov;58(11):1797-1804. doi: 10.2967/jnumed.117.192658. Epub 2017 Apr 27.
PubMed PMID: 28450569.


273: Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G,
Butticè S, Salonia A, Briganti A, Damiano R. Diagnostic Accuracy of (64)Copper
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed
Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate 
Cancer: Our Preliminary Experience. Urology. 2017 Aug;106:139-145. doi:
10.1016/j.urology.2017.04.019. Epub 2017 Apr 21. PubMed PMID: 28438628.


274: Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L,
Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C,
Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin
A, Czernin J, Herrmann K, Eiber M. (68)Ga-PSMA-11 PET/CT Interobserver Agreement 
for Prostate Cancer Assessments: An International Multicenter Prospective Study. 
J Nucl Med. 2017 Oct;58(10):1617-1623. doi: 10.2967/jnumed.117.190827. Epub 2017 
Apr 13. PubMed PMID: 28408531.


275: Daglioz Gorur G, Hekimsoy T, Isgoren S, Sikar Akturk A, Demir H. Uptake of
an Acrochordon Incidentally Detected on 68Ga Prostate-Specific Membrane Antigen
PET/CT. Clin Nucl Med. 2017 Jun;42(6):461-462. doi: 10.1097/RLU.0000000000001650.
PubMed PMID: 28368887.


276: McEwan LM, Wong D, Yaxley J. Flourodeoxyglucose positron emission tomography
scan may be helpful in the case of ductal variant prostate cancer when prostate
specific membrane antigen ligand positron emission tomography scan is negative. J
Med Imaging Radiat Oncol. 2017 Aug;61(4):503-505. doi: 10.1111/1754-9485.12605.
Epub 2017 Mar 28. PubMed PMID: 28349676.


277: Joshi A, Nicholson C, Rhee H, Gustafson S, Miles K, Vela I. Incidental
Malignancies Identified During Staging for Prostate Cancer With (68)Ga
Prostate-specific Membrane Antigen HBED-CC Positron Emission Tomography Imaging. 
Urology. 2017 Jun;104:e3-e4. doi: 10.1016/j.urology.2017.03.018. Epub 2017 Mar
20. PubMed PMID: 28336288.


278: Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE. (68)
Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after
surgery: Individualized medicine or new standard in salvage treatment. Prostate. 
2017 Jun;77(8):920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20. PubMed PMID:
28317152.


279: Kretschmer A, Herlemann A, Stief CG, Gratzke C. [When is surgical treatment 
indicated in metastatic prostate cancer and what is the scientific rationale?].
Urologe A. 2017 May;56(5):599-603. doi: 10.1007/s00120-017-0361-0. German. PubMed
PMID: 28314971.


280: Henkenberens C, VON Klot CA, Ross TL, Bengel FM, Wester HJ, Katja H,
Christiansen H, Derlin T. (68)Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph 
Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of
Systemic Therapy. Anticancer Res. 2017 Mar;37(3):1273-1279. PubMed PMID:
28314292.


281: Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F,
Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J,
Wan S, Wester HJ, Fanti S, Herrmann K. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI
procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol 
Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z. PubMed PMID:
28283702.


282: Singh A, Kulkarni HR, Baum RP. Imaging of Prostate Cancer Using
(64)Cu-Labeled Prostate-Specific Membrane Antigen Ligand. PET Clin. 2017
Apr;12(2):193-203. doi: 10.1016/j.cpet.2016.12.001. Epub 2017 Jan 31. Review.
PubMed PMID: 28267453.


283: Dureja S, Thakral P, Pant V, Sen I. Rare Sites of Metastases in Prostate
Cancer Detected on Ga-68 PSMA PET/CT Scan-A Case Series. Indian J Nucl Med. 2017 
Jan-Mar;32(1):13-15. doi: 10.4103/0972-3919.198450. PubMed PMID: 28242977; PubMed
Central PMCID: PMC5317062.


284: Ladwa R, Gustafson S, McCaffrey E, Miles K, O'Byrne K. A Rare Case of
Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response
to Systemic Therapy. Clin Nucl Med. 2017 Jun;42(6):e311-e312. doi:
10.1097/RLU.0000000000001619. PubMed PMID: 28240670.


285: Usmani S, Ahmed N, Marafi F, Rasheed R, Amanguno HG, Al Kandari F. Molecular
Imaging in Neuroendocrine Differentiation of Prostate Cancer: 68Ga-PSMA Versus
68Ga-DOTA NOC PET-CT. Clin Nucl Med. 2017 May;42(5):410-413. doi:
10.1097/RLU.0000000000001618. PubMed PMID: 28240661.


286: Will L, Sonni I, Kopka K, Kratochwil C, Giesel FL, Haberkorn U. Radiolabeled
prostate-specific membrane antigen small-molecule inhibitors. Q J Nucl Med Mol
Imaging. 2017 Jun;61(2):168-180. doi: 10.23736/S1824-4785.17.02977-6. Epub 2017
Feb 17. Review. PubMed PMID: 28217987.


287: Afaq A, Batura D, Bomanji J. New frontiers in prostate cancer imaging:
clinical utility of prostate-specific membrane antigen positron emission
tomography. Int Urol Nephrol. 2017 May;49(5):803-810. doi:
10.1007/s11255-017-1541-y. Epub 2017 Feb 14. Review. PubMed PMID: 28197764.


288: Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental
Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT. Clin
Nucl Med. 2017 Apr;42(4):e218-e220. doi: 10.1097/RLU.0000000000001569. PubMed
PMID: 28166149.


289: Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, 
Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
(68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason
score predict the intensity of tracer accumulation in the primary tumour. Eur J
Nucl Med Mol Imaging. 2017 Jun;44(6):941-949. doi: 10.1007/s00259-017-3631-6.
Epub 2017 Jan 31. PubMed PMID: 28138747.


290: Giesel FL, Kesch C, Yun M, Cardinale J, Haberkorn U, Kopka K, Kratochwil C, 
Hadaschik BA. 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With
Biochemically Recurrent Prostate Cancer. Clin Genitourin Cancer. 2017
Jun;15(3):e497-e499. doi: 10.1016/j.clgc.2016.12.029. Epub 2016 Dec 29. PubMed
PMID: 28131751.


291: Jain TK, Jois AG, Kumar V S, Singh SK, Kumar R, Mittal BR. Incidental
detection of tracer avidity in meningioma in (68)Ga-PSMA PET/CT during initial
staging for prostate cancer. Rev Esp Med Nucl Imagen Mol. 2017 Mar -
Apr;36(2):133-134. doi: 10.1016/j.remn.2016.10.005. Epub 2017 Jan 26. English,
Spanish. PubMed PMID: 28131698.


292: Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of
(68) Ga prostate specific membrane antigen - positron emission tomography in
diagnosis and response assessment of recurrent renal cell carcinoma. J Med
Imaging Radiat Oncol. 2017 Jun;61(3):372-378. doi: 10.1111/1754-9485.12590. Epub 
2017 Jan 24. Review. PubMed PMID: 28116853.


293: Zang S, Shao G, Cui C, Li TN, Huang Y, Yao X, Fan Q, Chen Z, Du J, Jia R,
Sun H, Hua Z, Tang J, Wang F. 68Ga-PSMA-11 PET/CT for prostate cancer staging and
risk stratification in Chinese patients. Oncotarget. 2017 Feb
14;8(7):12247-12258. doi: 10.18632/oncotarget.14691. PubMed PMID: 28103574;
PubMed Central PMCID: PMC5355341.


294: Murphy DG, Hofman M, Lawrentschuk N, Maurer T. Bringing clarity or
confusion? The role of prostate-specific membrane antigen
positron-emission/computed tomography for primary staging in prostate cancer. BJU
Int. 2017 Feb;119(2):194-195. doi: 10.1111/bju.13600. PubMed PMID: 28090758.


295: Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, 
Uprimny C, Lukas P, Horninger W, Virgolini I. The (68)Ga/(177)Lu theragnostic
concept in PSMA targeting of castration-resistant prostate cancer: correlation of
SUV(max) values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017
May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12. PubMed PMID:
28083690.


296: Bräuer A, Rahbar K, Konnert J, Bögemann M, Stegger L. Diagnostic value of
additional (68)Ga-PSMA-PET before (223)Ra-dichloride therapy in patients with
metastatic prostate carcinoma. Nuklearmedizin. 2017 Feb 14;56(1):14-22. doi:
10.3413/Nukmed-0846-16-09. Epub 2017 Jan 11. PubMed PMID: 28074210.


297: Noto B, Weckesser M, Buerke B, Pixberg M, Avramovic N. Gastrointestinal
Stromal Tumor Showing Intense Tracer Uptake on PSMA PET/CT. Clin Nucl Med. 2017
Mar;42(3):200-202. doi: 10.1097/RLU.0000000000001491. PubMed PMID: 28072616.


298: Zacho HD, Nielsen JB, Dettmann K, Haberkorn U, Petersen LJ. Incidental
Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT 
to Assess Prostate Cancer Recurrence. Clin Nucl Med. 2017 Mar;42(3):221-222. doi:
10.1097/RLU.0000000000001522. PubMed PMID: 28033223.


299: Beheshti M, Rezaee A, Langsteger W. 68Ga-PSMA-HBED Uptake on Cervicothoracic
(Stellate) Ganglia, a Common Pitfall on PET/CT. Clin Nucl Med. 2017
Mar;42(3):195-196. doi: 10.1097/RLU.0000000000001518. PubMed PMID: 28033219.


300: Gasch C, Düwel C, Kopka K, Kratochwil C, Vinsensia M, Eiber M, Maurer T,
Haberkorn U, Hadaschik B, Giesel FL. [Significance of PSMA imaging in prostate
cancer]. Urologe A. 2017 Jan;56(1):3-12. doi: 10.1007/s00120-016-0293-0. German. 
PubMed PMID: 28005153.


301: Chan M, Hsiao E. Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA
PET/CT. Clin Nucl Med. 2017 Feb;42(2):110-111. doi: 10.1097/RLU.0000000000001489.
PubMed PMID: 27997426.


302: Sathianathen NJ, Lamb A, Nair R, Geurts N, Mitchell C, Lawrentschuk NL, Moon
DA, Murphy DG. Updates of prostate cancer staging: Prostate-specific membrane
antigen. Investig Clin Urol. 2016 Dec;57(Suppl 2):S147-S154. Epub 2016 Nov 30.
Review. PubMed PMID: 27995218; PubMed Central PMCID: PMC5161015.


303: Damle NA, Tripathi M, Chakraborty PS, Sahoo MK, Bal C, Aggarwal S, Arora G, 
Kumar P, Kumar R, Gupta R. Unusual Uptake of Prostate Specific Tracer
(68)Ga-PSMA-HBED-CC in a Benign Thyroid Nodule. Nucl Med Mol Imaging. 2016
Dec;50(4):344-347. Epub 2016 Mar 22. PubMed PMID: 27994690; PubMed Central PMCID:
PMC5135692.


304: Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG,
Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ. Early dynamic
imaging in (68)Ga- PSMA-11 PET/CT allows discrimination of urinary bladder
activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017
May;44(5):765-775. doi: 10.1007/s00259-016-3578-z. Epub 2016 Nov 29. PubMed PMID:
27900519.


305: Krohn T, Birmes A, Winz OH, Drude NI, Mottaghy FM, Behrendt FF, Verburg FA. 
The reconstruction algorithm used for [(68)Ga]PSMA-HBED-CC PET/CT reconstruction 
significantly influences the number of detected lymph node metastases and coeliac
ganglia. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):662-669. doi:
10.1007/s00259-016-3571-6. Epub 2016 Nov 29. PubMed PMID: 27900518.


306: Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A,
Obek C, Kural AR. The role of PSMA PET/CT imaging in restaging of prostate cancer
patients with low prostate-specific antigen levels. Nucl Med Commun. 2017
Feb;38(2):149-155. doi: 10.1097/MNM.0000000000000617. PubMed PMID: 27893589.


307: Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch
C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W,
Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution,
radiation dosimetry and histopathological validation of tumor lesions in prostate
cancer patients. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi:
10.1007/s00259-016-3573-4. Epub 2016 Nov 26. PubMed PMID: 27889802; PubMed
Central PMCID: PMC5323462.


308: Stephens M, Kim DI, Shepherd B, Gustafson S, Thomas P. Intense Uptake in
Amyloidosis of the Seminal Vesicles on 68Ga-PSMA PET Mimicking Locally Advanced
Prostate Cancer. Clin Nucl Med. 2017 Feb;42(2):147-148. doi:
10.1097/RLU.0000000000001460. PubMed PMID: 27879490.


309: Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, Haller
B, Schwaiger M, Gschwend JE, Eiber M, Maurer T. Value of (111)
In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage
lymphadenectomy in recurrent prostate cancer: correlation with histopathology and
clinical follow-up. BJU Int. 2017 Jul;120(1):40-47. doi: 10.1111/bju.13713. Epub 
2016 Dec 4. PubMed PMID: 27862863.


310: Lütje S, Gomez B, Cohnen J, Umutlu L, Gotthardt M, Poeppel TD, Bockisch A,
Rosenbaum-Krumme S. Imaging of Prostate-Specific Membrane Antigen Expression in
Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT. Clin
Nucl Med. 2017 Jan;42(1):20-25. PubMed PMID: 27846003.


311: Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and Radionuclide Therapy in
Prostate Cancer. Semin Nucl Med. 2016 Nov;46(6):522-535. doi:
10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3. Review. PubMed PMID: 27825432;
PubMed Central PMCID: PMC5123597.


312: Schuster DM, Nanni C, Fanti S. PET Tracers Beyond FDG in Prostate Cancer.
Semin Nucl Med. 2016 Nov;46(6):507-521. doi: 10.1053/j.semnuclmed.2016.07.005.
Epub 2016 Sep 7. Review. PubMed PMID: 27825431; PubMed Central PMCID: PMC5117950.


313: Porres D, Pfister D, Thissen A, Kuru TH, Zugor V, Buettner R, Knuechel R,
Verburg FA, Heidenreich A. The role of salvage extended lymph node dissection in 
patients with rising PSA and PET/CT scan detected nodal recurrence of prostate
cancer. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):85-92. doi:
10.1038/pcan.2016.54. Epub 2016 Nov 8. PubMed PMID: 27824042.


314: Malik D, Basher RK, Mittal BR, Jain TK, Bal A, Singh SK. 68Ga-PSMA
Expression in Pseudoangiomatous Stromal Hyperplasia of the Breast. Clin Nucl Med.
2017 Jan;42(1):58-60. PubMed PMID: 27819857.


315: Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A,
Gschwend JE, Schwaiger M, Eiber M. Value of 68Ga-PSMA HBED-CC PET for the
Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical 
Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. J Nucl 
Med. 2016 Nov;57(11):1713-1719. Epub 2016 Jun 3. PubMed PMID: 27261524.


316: Barrio M, Fendler WP, Czernin J, Herrmann K. Prostate specific membrane
antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev
Mol Diagn. 2016 Nov;16(11):1177-1188. Epub 2016 Oct 14. Review. PubMed PMID:
27679869.


317: Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.
The use of (68 ) Ga-PSMA PET CT in men with biochemical recurrence after
definitive treatment of acinar prostate cancer. BJU Int. 2016 Oct;118 Suppl
3:49-55. doi: 10.1111/bju.13616. Epub 2016 Sep 23. PubMed PMID: 27659411.


318: Rhee H, Blazak J, Tham CM, Ng KL, Shepherd B, Lawson M, Preston J, Vela I,
Thomas P, Wood S. Pilot study: use of gallium-68 PSMA PET for detection of
metastatic lesions in patients with renal tumour. EJNMMI Res. 2016 Dec;6(1):76.
Epub 2016 Oct 22. PubMed PMID: 27771904; PubMed Central PMCID: PMC5075321.


319: Michaud L, Touijer KA. [Focus on molecular imaging in prostate cancer]. Prog
Urol. 2016 Sep - Oct;26(11-12):619-627. doi: 10.1016/j.purol.2016.08.017. Epub
2016 Sep 20. Review. French. PubMed PMID: 27663306; PubMed Central PMCID:
PMC5588868.


320: Schreiter V, Reimann C, Geisel D, Schreiter NF. Nuclear Medicine Imaging of 
Prostate Cancer. Rofo. 2016 Nov;188(11):1037-1044. Epub 2016 Jun 14. Review.
PubMed PMID: 27299668.


321: Incerti E, Mapelli P, Gianolli L, Picchio M. PET imaging for lymph node
dissection in prostate cancer. World J Urol. 2017 Apr;35(4):507-515. doi:
10.1007/s00345-016-1954-8. Epub 2016 Oct 17. Review. PubMed PMID: 27752756.


322: Derlin T, Weiberg D, Sohns JM. Multitracer Molecular Imaging of Paget
Disease Targeting Bone Remodeling, Fatty Acid Metabolism, and PSMA Expression on 
PET/CT. Clin Nucl Med. 2016 Dec;41(12):991-992. PubMed PMID: 27749427.


323: Sasikumar A, Joy A, Nanabala R, Unni M, Tk P. Complimentary Pattern of
Uptake in 18F-FDG PET/CT and 68Ga-Prostate-Specific Membrane Antigen PET/CT in a 
Case of Metastatic Clear Cell Renal Carcinoma. Clin Nucl Med. 2016
Dec;41(12):e517-e519. PubMed PMID: 27749421.


324: Bhardwaj H, Stephens M, Bhatt M, Thomas PA. Prostate-Specific Membrane
Antigen PET/CT Findings for Hepatic Hemangioma. Clin Nucl Med. 2016
Dec;41(12):968-969. PubMed PMID: 27749413.


325: Bode A, Rahbar K, Konnert J, Bögemann M, Stegger L. Benefit of
68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy. Clin Nucl
Med. 2016 Dec;41(12):951-952. PubMed PMID: 27749411.


326: Hermann RM, Djannatian M, Czech N, Nitsche M. Prostate-Specific Membrane
Antigen PET/CT: False-Positive Results due to Sarcoidosis? Case Rep Oncol. 2016
Aug 17;9(2):457-463. eCollection 2016 May-Aug. PubMed PMID: 27721768; PubMed
Central PMCID: PMC5043264.


327: Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, Floth A, Righi
S, Zandieh S, Meleddu C, Shariat SF, Klingler HC, Mirzaei S. (64)Cu-PSMA-617
PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. Cancer Biother
Radiopharm. 2016 Oct;31(8):277-286. doi: 10.1089/cbr.2015.1964. Epub 2016 Oct 7. 
PubMed PMID: 27715146.


328: Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, Larson SM.
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis
Imaging. J Nucl Med. 2016 Oct;57(Suppl 3):73S-78S. PubMed PMID: 27694177.


329: Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, Stief C,
Bartenstein P, Gratzke C, Lehner S, Rominger A. Preliminary experience with
dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for
metastatic castration-resistant prostate cancer. Oncotarget. 2017 Jan
10;8(2):3581-3590. doi: 10.18632/oncotarget.12240. PubMed PMID: 27683041; PubMed 
Central PMCID: PMC5356905.


330: Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T,
Kauczor HU, Schwartz LH, Haberkorn U, Flechsig P. Correlation Between SUVmax and 
CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
J Nucl Med. 2017 Feb;58(2):282-287. doi: 10.2967/jnumed.116.179648. Epub 2016 Sep
22. PubMed PMID: 27660141.


331: Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA Uptake in
Hepatocellular Carcinoma. Clin Nucl Med. 2017 Jan;42(1):e69-e70. PubMed PMID:
27607177.


332: Heidenreich A, Moul JW, Shariat S, Karnes RJ. Role of salvage lymph node
dissection in prostate cancer. Curr Opin Urol. 2016 Nov;26(6):581-9. doi:
10.1097/MOU.0000000000000343. Review. PubMed PMID: 27584024.


333: Rhee H, Ng KL, Tse BW, Yeh MC, Russell PJ, Nelson C, Thomas P, Samaratunga
H, Vela I, Gobe G, Wood S. Using prostate specific membrane antigen (PSMA)
expression in clear cell renal cell carcinoma for imaging advanced disease.
Pathology. 2016 Oct;48(6):613-6. doi: 10.1016/j.pathol.2016.05.011. Epub 2016 Aug
24. PubMed PMID: 27567227.


334: Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg
C, la Fougère C. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the
detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging.
2017 Jan;44(1):92-101. Epub 2016 Aug 24. PubMed PMID: 27557844.


335: Derlin T, Schumacher U, Bengel FM. Nonneoplastic Neuroma After Radical
Prostatectomy Is Not a Mimicker of Lymph Node Metastases on 68Ga-PSMA Ligand
PET/CT. Clin Nucl Med. 2016 Oct;41(10):785-6. doi: 10.1097/RLU.0000000000001333. 
PubMed PMID: 27556791.


336: Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current
Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine:
Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen
Ligands Into Diagnostics and Therapy for Prostate Cancer. Semin Nucl Med. 2016
Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004. Review. PubMed PMID:
27553466.


337: Henninger M, Maurer T, Hacker C, Eiber M. 68Ga-PSMA PET/MR Showing Intense
PSMA Uptake in Nodular Fasciitis Mimicking Prostate Cancer Metastasis. Clin Nucl 
Med. 2016 Oct;41(10):e443-4. doi: 10.1097/RLU.0000000000001310. PubMed PMID:
27488427.


338: Düwel C, Eiber M, Maurer T. [Will 68Ga-PSMA PET become the New Imaging
Standard for Prostate Cancer?]. Aktuelle Urol. 2016 Sep;47(5):378-82. doi:
10.1055/s-0042-110982. Epub 2016 Jul 28. Review. German. PubMed PMID: 27467591.


339: Morigi JJ, Fanti S, Murphy D, Hofman MS. Rapidly changing landscape of
PET/CT imaging in prostate cancer. Curr Opin Urol. 2016 Sep;26(5):493-500. doi:
10.1097/MOU.0000000000000309. Review. PubMed PMID: 27467137.


340: Verburg FA, Pfestroff A. Imaging: PSMA PET-CT in initial prostate cancer
staging. Nat Rev Urol. 2016 Sep;13(9):498-9. doi: 10.1038/nrurol.2016.136. Epub
2016 Jul 19. Review. PubMed PMID: 27431335.


341: Kanthan GL, Izard MA, Emmett L, Hsiao E, Schembri GP. Schwannoma Showing
Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016 Sep;41(9):703-4.
doi: 10.1097/RLU.0000000000001281. PubMed PMID: 27405039.


342: Gupta M, Choudhury PS, Gupta G, Gandhi J. Metastasis in urothelial carcinoma
mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen 
positron emission tomography-computed tomography in a case of synchronous
malignancy. Indian J Nucl Med. 2016 Jul-Sep;31(3):222-4. doi:
10.4103/0972-3919.183615. PubMed PMID: 27385897; PubMed Central PMCID:
PMC4918490.


343: Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D,
Lawrentschuk N. Sensitivity, Specificity, and Predictors of Positive
(68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in
Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016
Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. Review.
PubMed PMID: 27363387.


344: Basu S, Alavi A. PET-Based Personalized Management in Clinical Oncology: An 
Unavoidable Path for the Foreseeable Future. PET Clin. 2016 Jul;11(3):203-7. doi:
10.1016/j.cpet.2016.03.002. Epub 2016 May 2. Review. PubMed PMID: 27321025.


345: Maurer T, Schwamborn K, Schottelius M, Wester HJ, Schwaiger M, Gschwend JE, 
Eiber M. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in
Recurrent Prostate Cancer. Clin Genitourin Cancer. 2016 Oct;14(5):e549-e552. doi:
10.1016/j.clgc.2016.05.020. Epub 2016 May 27. PubMed PMID: 27318956.


346: Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N,
Schwaiger M, Maurer T, Eiber M. Comparison of bone scintigraphy and (68)Ga-PSMA
PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016
Nov;43(12):2114-2121. Epub 2016 Jun 12. PubMed PMID: 27290607.


347: Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M.
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and
report. Cancer Imaging. 2016 Jun 8;16(1):14. doi: 10.1186/s40644-016-0072-6.
Review. PubMed PMID: 27277843; PubMed Central PMCID: PMC4898465.


348: Queiroz MA, Viana P, Santos A, Bastos D, Etchebehere E, Cerri G. Clinical
Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate
Cancer. Clin Nucl Med. 2016 Sep;41(9):e417-9. doi: 10.1097/RLU.0000000000001264. 
PubMed PMID: 27276202.


349: Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, 
Vogel-Claussen J, Christiansen H, Derlin T. (68)Ga-PSMA ligand PET/CT-based
radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer :
Early efficacy after primary therapy. Strahlenther Onkol. 2016 Jul;192(7):431-9. 
doi: 10.1007/s00066-016-0982-z. Epub 2016 Jun 7. PubMed PMID: 27272755.


350: Buck A, Decristoforo C. Highlights lecture EANM 2015: the search for nuclear
medicine's superheroes. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1910-27. doi:
10.1007/s00259-016-3423-4. Epub 2016 May 27. PubMed PMID: 27229941; PubMed
Central PMCID: PMC4969359.


351: Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, Gschwend JE, 
Combs SE, Habl G. Integration of (68)Ga-PSMA-PET imaging in planning of primary
definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol. 
2016 May 26;11:73. doi: 10.1186/s13014-016-0646-2. PubMed PMID: 27229485; PubMed 
Central PMCID: PMC4882861.


352: Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, Nelson C,
Chung E, Wood G, Malone G, Wood S, Heathcote P. Prostate Specific Membrane
Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of
Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. J Urol. 
2016 Oct;196(4):1261-7. doi: 10.1016/j.juro.2016.02.3000. Epub 2016 May 21.
PubMed PMID: 27220897.


353: van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron
emission tomography/computed tomography for preoperative lymph node staging in
prostate cancer. BJU Int. 2017 Feb;119(2):209-215. doi: 10.1111/bju.13540. Epub
2016 Jun 18. PubMed PMID: 27207581.


354: Jadvar H. Positron emission tomography in imaging evaluation of staging,
restaging, treatment response, and prognosis in prostate cancer. Abdom Radiol
(NY). 2016 May;41(5):889-98. doi: 10.1007/s00261-015-0563-0. Review. PubMed PMID:
27193789; PubMed Central PMCID: PMC5412588.


355: O'Kane DB, Lawrentschuk N, Bolton DM. Prostate cancer nodal oligometastasis 
accurately assessed using prostate-specific membrane antigen positron emission
tomography-computed tomography and confirmed histologically following
robotic-assisted lymph node dissection. Urol Ann. 2016 Apr-Jun;8(2):255-7. doi:
10.4103/0974-7796.179237. PubMed PMID: 27141207; PubMed Central PMCID:
PMC4839254.


356: Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.
PET imaging of prostate-specific membrane antigen in prostate cancer: current
state of the art and future challenges. Prostate Cancer Prostatic Dis. 2016
Sep;19(3):223-30. doi: 10.1038/pcan.2016.13. Epub 2016 May 3. Review. PubMed
PMID: 27136743; PubMed Central PMCID: PMC4982789.


357: Lavalaye J, Kaldeway P, van Melick HH. Diffuse bone metastases on
(68)Ga-PSMA PET-CT in a patient with prostate cancer and normal bone scan. Eur J 
Nucl Med Mol Imaging. 2016 Jul;43(8):1563-4. doi: 10.1007/s00259-016-3398-1. Epub
2016 Apr 28. PubMed PMID: 27121692.


358: Mottaghy FM, Heinzel A, Verburg FA. Molecular imaging using PSMA PET/CT
versus multiparametric MRI for initial staging of prostate cancer: comparing
apples with oranges? Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1397-9. doi:
10.1007/s00259-016-3389-2. Epub 2016 Apr 27. PubMed PMID: 27118189.


359: Langsteger W, Rezaee A, Loidl W, Geinitz HS, Fitz F, Steinmair M, Broinger
G, Pallwien-Prettner L, Beheshti M, Imamovic L, Beheshti M, Rendl G, Hackl D,
Tsybrovsky O, Steinmair M, Emmanuel K, Moinfar F, Pirich C, Langsteger W, Bytyqi 
A, Karanikas G, Mayerhöfer M, Koperek O, Niederle B, Hartenbach M, Beyer T,
Herrmann K, Czernin J, Rausch I, Rust P, DiFranco MD, Lassen M, Stadlbauer A,
Mayerhöfer ME, Hartenbach M, Hacker M, Beyer T, Binzel K, Magnussen R, Wei W,
Knopp MU, Flanigan DC, Kaeding C, Knopp MV, Leisser A, Nejabat M, Hartenbach M,
Kramer G, Krainer M, Hacker M, Haug A, Lehnert W, Schmidt K, Kimiaei S, Bronzel
M, Kluge A, Wright CL, Binzel K, Zhang J, Wuthrick E, Maniawski P, Knopp MV,
Blaickner M, Rados E, Huber A, Dulovits M, Kulkarni H, Wiessalla S, Schuchardt C,
Baum RP, Knäusl B, Georg D, Bauer M, Wulkersdorfer B, Wadsak W, Philippe C,
Haslacher H, Zeitlinger M, Langer O, Bauer M, Feldmann M, Karch R, Wadsak W,
Zeitlinger M, Koepp MJ, Asselin MC, Pataraia E, Langer O, Zeilinger M, Philippe
C, Dumanic M, Pichler F, Pilz J, Hacker M, Wadsak W, Mitterhauser M, Nics L,
Steiner B, Hacker M, Mitterhauser M, Wadsak W, Traxl A, Wanek T, Kryeziu K,
Mairinger S, Stanek J, Berger W, Kuntner C, Langer O, Mairinger S, Wanek T, Traxl
A, Krohn M, Stanek J, Filip T, Sauberer M, Kuntner C, Pahnke J, Langer O,
Svatunek D, Denk C, Wilkovitsch M, Wanek T, Filip T, Kuntner-Hannes C, Fröhlich
J, Mikula H, Denk C, Svatunek D, Wanek T, Mairinger S, Stanek J, Filip T,
Fröhlich J, Mikula H, Kuntner-Hannes C, Balber T, Singer J, Fazekas J, Rami-Mark 
C, Berroterán-Infante N, Jensen-Jarolim E, Wadsak W, Hacker M, Viernstein H,
Mitterhauser M, Denk C, Svatunek D, Sohr B, Mikula H, Fröhlich J, Wanek T,
Kuntner-Hannes C, Filip T, Pfaff S, Philippe C, Mitterhauser M, Hartenbach M,
Hacker M, Wadsak W, Wanek T, Halilbasic E, Visentin M, Mairinger S, Stieger B,
Kuntner C, Trauner M, Langer O, Lam P, Aistleitner M, Eichinger R, Artner C,
Eidherr H, Vraka C, Haug A, Mitterhauser M, Nics L, Hartenbach M, Hacker M,
Wadsak W, Kvaternik H, Müller R, Hausberger D, Zink C, Aigner RM, Cossío U,
Asensio M, Montes A, Akhtar S, Te Welscher Y, van Nostrum R, Gómez-Vallejo V,
Llop J, VandeVyver F, Barclay T, Lippens N, Troch M, Hehenwarter L, Egger B,
Holzmannhofer J, Rodrigues-Radischat M, Pirich C, Pötsch N, Rausch I, Wilhelm D, 
Weber M, Furtner J, Karanikas G, Wöhrer A, Mitterhauser M, Hacker M,
Traub-Weidinger T, Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V,
Kerrou K, Devaux JY, Mohty M, Garderet L, Talbot JN, Stanzel S, Pregartner G,
Schwarz T, Bjelic-Radisic V, Liegl-Atzwanger B, Aigner R, Stanzel S, Quehenberger
F, Aigner RM, Marković AK, Janković M, Jerković VM, Paskaš M, Pupić G, Džodić R, 
Popović D, Fornito MC, Familiari D, Koranda P, Polzerová H, Metelková I, Henzlová
L, Formánek R, Buriánková E, Kamínek M, Thomson WH, Lewis C, Thomson WH, O'Brien 
J, James G, Notghi A, Huber H, Stelzmüller I, Wunn R, Mandl M, Fellner F,
Lamprecht B, Gabriel M, Fornito MC, Leonardi G, Thomson WH, O'Brien J, James G,
Hudzietzová J, Sabol J, Fülöp M. 32nd International Austrian Winter Symposium :
Zell am See, the Netherlands. 20-23 January 2016. EJNMMI Res. 2016 Apr;6(Suppl
1):32. doi: 10.1186/s13550-016-0168-9. Epub 2016 Apr 18. PubMed PMID: 27090254;
PubMed Central PMCID: PMC4835428.


360: Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, 
Ahmadzadehfar H. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in 
Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter
Retrospective Analysis. J Nucl Med. 2016 Sep;57(9):1334-8. doi:
10.2967/jnumed.116.173757. Epub 2016 Apr 7. PubMed PMID: 27056618.


361: Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W.
Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer:
Characterization of Uptake in Normal Organs and Tumour Lesions. Mol Imaging Biol.
2016 Jun;18(3):428-36. doi: 10.1007/s11307-016-0945-x. PubMed PMID: 27038316.


362: Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL,
Christiansen H, Merseburger AS, Bengel FM. (68)Ga-PSMA I&T PET/CT for assessment 
of prostate cancer: evaluation of image quality after forced diuresis and delayed
imaging. Eur Radiol. 2016 Dec;26(12):4345-4353. Epub 2016 Mar 24. PubMed PMID:
27011373.


363: Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, Antoch G,
Hautzel H. Diagnostic potential of PET/CT using a (68)Ga-labelled
prostate-specific membrane antigen ligand in whole-body staging of renal cell
carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2017
Jan;44(1):102-107. Epub 2016 Mar 21. PubMed PMID: 26996777.


364: Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M,
Afshar-Oromieh A, Kopka K, Debus J, Haberkorn U, Kratochwil C. Intra-individual
comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of
primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1400-6. doi: 
10.1007/s00259-016-3346-0. Epub 2016 Mar 14. PubMed PMID: 26971788; PubMed
Central PMCID: PMC4906063.


365: Sager S, Vatankulu B, Uslu L, Sönmezoglu K. Incidental Detection of
Follicular Thyroid Carcinoma in 68Ga-PSMA PET/CT Imaging. J Nucl Med Technol.
2016 Sep;44(3):199-200. doi: 10.2967/jnmt.115.171660. Epub 2016 Mar 10. PubMed
PMID: 26966127.


366: Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular Lymphoma
Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016
Jun;41(6):500-1. doi: 10.1097/RLU.0000000000001169. PubMed PMID: 26914565.


367: Kanthan GL, Hsiao E, Kneebone A, Eade T, Schembri GP. Desmoid Tumor Showing 
Intense Uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016 Jun;41(6):508-9. 
doi: 10.1097/RLU.0000000000001192. PubMed PMID: 26909712.


368: Soydal C, Ozkan E, Yerlikaya H, Utkan G, Kucuk ON. Widespread Metastatic
Prostate Carcinoma Shown by 68Ga-PSMA PET/CT. Clin Nucl Med. 2016
Jun;41(6):e294-5. doi: 10.1097/RLU.0000000000001176. PubMed PMID: 26909710.


369: Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in
prostate cancer management. Nat Rev Urol. 2016 Apr;13(4):226-35. doi:
10.1038/nrurol.2016.26. Epub 2016 Feb 23. Review. PubMed PMID: 26902337.


370: Hijazi S, Meller B, Leitsmann C, Strauss A, Ritter C, Lotz J, Meller J,
Trojan L, Sahlmann CO. See the unseen: Mesorectal lymph node metastases in
prostate cancer. Prostate. 2016 Jun;76(8):776-80. doi: 10.1002/pros.23168. Epub
2016 Feb 16. PubMed PMID: 26880517.


371: Geraldo L, Ceci F, Uprimny C, Kendler D, Virgolini I. Detection of
Sarcomatoid Lung Metastasis With 68GA-PSMA PET/CT in a Patient With Prostate
Cancer. Clin Nucl Med. 2016 May;41(5):421-2. doi: 10.1097/RLU.0000000000001157.
PubMed PMID: 26859209.


372: Einspieler I, Tauber R, Maurer T, Schwaiger M, Eiber M. 68Ga
Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node
Metastases. Clin Nucl Med. 2016 May;41(5):e261-2. doi:
10.1097/RLU.0000000000001128. PubMed PMID: 26859205.


373: Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C,
Thalmann GN, Picchio M. New Clinical Indications for (18)F/(11)C-choline, New
Tracers for Positron Emission Tomography and a Promising Hybrid Device for
Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol. 2016
Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2. Review.
PubMed PMID: 26850970.


374: Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga
Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung
Cancer. Clin Nucl Med. 2016 May;41(5):414-6. doi: 10.1097/RLU.0000000000001139.
PubMed PMID: 26828144.


375: Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C,
Gildehaus FJ, Stief CG, Gratzke C, Fendler WP. (68)Ga-PSMA Positron Emission
Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions
Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol. 2016
Oct;70(4):553-557. doi: 10.1016/j.eururo.2015.12.051. Epub 2016 Jan 19. PubMed
PMID: 26810345.


376: van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen 
Q, Ho B, Emmett L. (68) Ga-PSMA has a high detection rate of prostate cancer
recurrence outside the prostatic fossa in patients being considered for salvage
radiation treatment. BJU Int. 2016 May;117(5):732-9. doi: 10.1111/bju.13397. Epub
2016 Jan 24. PubMed PMID: 26683282.


377: Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G,
Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M. Diagnostic Efficacy
of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging
for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk
Prostate Cancer. J Urol. 2016 May;195(5):1436-1443. doi:
10.1016/j.juro.2015.12.025. Epub 2015 Dec 9. PubMed PMID: 26682756.


378: Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA,
Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC. PSMA Ligands
for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Theranostics. 2015 Oct 18;5(12):1388-401. doi: 10.7150/thno.13348. eCollection
2015. Review. PubMed PMID: 26681984; PubMed Central PMCID: PMC4672020.


379: Shakespeare TP. Effect of prostate-specific membrane antigen positron
emission tomography on the decision-making of radiation oncologists. Radiat
Oncol. 2015 Nov 18;10:233. doi: 10.1186/s13014-015-0548-8. PubMed PMID: 26582424;
PubMed Central PMCID: PMC4652371.


380: Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, 
Behrendt FF. Extent of disease in recurrent prostate cancer determined by
[(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and
Gleason score. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403. doi:
10.1007/s00259-015-3240-1. Epub 2015 Nov 12. PubMed PMID: 26563121.


381: Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K,
Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A. Comparison of hybrid
(68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and
bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016
Jan;43(1):70-83. doi: 10.1007/s00259-015-3206-3. Epub 2015 Oct 28. PubMed PMID:
26508290.


382: Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K,
Afshar-Oromieh A, Debus J, Haberkorn U, Giesel FL. (68)Ga-PSMA-11 PET/CT: a new
technique with high potential for the radiotherapeutic management of prostate
cancer patients. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):34-41. doi:
10.1007/s00259-015-3188-1. Epub 2015 Sep 25. PubMed PMID: 26404016; PubMed
Central PMCID: PMC4771815.


383: Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal
adenoma. J Med Imaging Radiat Oncol. 2016 Aug;60(4):514-7. doi:
10.1111/1754-9485.12357. Epub 2015 Sep 23. PubMed PMID: 26394552.


384: Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J,
Schildhaus HU, Trojan L, Sahlmann CO. Pelvic lymph node dissection for nodal
oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission
tomography/computerized tomography. Prostate. 2015 Dec;75(16):1934-40. doi:
10.1002/pros.23091. Epub 2015 Sep 10. PubMed PMID: 26356236.


385: Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY,
Pomper MG, Allaf ME. Imaging of metastatic clear cell renal cell carcinoma with
PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann Nucl Med. 2015 Dec;29(10):877-82. doi:
10.1007/s12149-015-1017-z. Epub 2015 Aug 19. PubMed PMID: 26286635; PubMed
Central PMCID: PMC4666821.


386: Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, Moltz JH,
Afshar-Oromieh A, Choyke PL, Haberkorn U, Kratochwil C. PSMA PET/CT with
Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment 
in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015
Nov;42(12):1794-800. doi: 10.1007/s00259-015-3106-6. Epub 2015 Jul 11. PubMed
PMID: 26162799; PubMed Central PMCID: PMC4589548.


387: Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen
M, Steuber T, Rosenbaum C. Initial Experience of (68)Ga-PSMA PET/CT Imaging in
High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol. 2016
Mar;69(3):393-6. doi: 10.1016/j.eururo.2015.06.010. Epub 2015 Jun 25. PubMed
PMID: 26116958.


388: Maurer T, Kübler H, Gschwend JE, Eiber M. [Positron-emission tomography in
urooncology]. Urologe A. 2015 Jul;54(7):983-91. doi: 10.1007/s00120-015-3868-2.
German. Erratum in: Urologe A. 2015 Sep;54(9):1293. PubMed PMID: 26109122.


389: Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni
HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ. 68Ga- and
177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and
First Proof-of-Concept Human Studies. J Nucl Med. 2015 Aug;56(8):1169-76. doi:
10.2967/jnumed.115.158550. Epub 2015 Jun 18. PubMed PMID: 26089548.


390: Lawal I, Vorster M, Boshomane T, Ololade K, Ebenhan T, Sathekge M.
Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT. Clin
Nucl Med. 2015 Sep;40(9):755-6. doi: 10.1097/RLU.0000000000000870. PubMed PMID:
26053729.


391: Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J,
Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ.
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are
associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015
Jul;42(8):1284-94. doi: 10.1007/s00259-015-3078-6. Epub 2015 May 15. PubMed PMID:
25975367.


392: Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, Kübler H,
Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend JE, Eiber M.
Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes
in prostate cancer. Eur Urol. 2015 Sep;68(3):530-4. doi:
10.1016/j.eururo.2015.04.034. Epub 2015 May 6. PubMed PMID: 25957851.


393: Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M,
Talat Z, Araman A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand 
in patients with prostate cancer and the value of early pelvic imaging. Nucl Med 
Commun. 2015 Jun;36(6):582-7. doi: 10.1097/MNM.0000000000000290. PubMed PMID:
25738559.


394: Bouchelouche K, Turkbey B, Choyke PL. Advances in imaging modalities in
prostate cancer. Curr Opin Oncol. 2015 May;27(3):224-31. doi:
10.1097/CCO.0000000000000174. Review. PubMed PMID: 25715326.


395: Chakraborty PS, Kumar R, Tripathi M, Das CJ, Bal C. Detection of brain
metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging 
of prostate carcinoma. Clin Nucl Med. 2015 Apr;40(4):328-9. doi:
10.1097/RLU.0000000000000709. PubMed PMID: 25674861.


396: Demirkol MO, Acar Ö, Uçar B, Ramazanoğlu SR, Sağlıcan Y, Esen T.
Prostate-specific membrane antigen-based imaging in prostate cancer: impact on
clinical decision making process. Prostate. 2015 May;75(7):748-57. doi:
10.1002/pros.22956. Epub 2015 Jan 18. PubMed PMID: 25598074.


397: Hellwig D, Moosbauer J, Eilles C. [Ga-68-PSMA PET/CT for prostate cancer].
Aktuelle Urol. 2014 Nov;45(6):457-63. doi: 10.1055/s-0034-1395529. Epub 2014 Dec 
17. Review. German. PubMed PMID: 25518963.


398: Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, Schwaiger M.
(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.
Abdom Imaging. 2015 Aug;40(6):1769-71. doi: 10.1007/s00261-014-0301-z. PubMed
PMID: 25412869.


399: Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, Mottaghy FM,
Behrendt FF. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac 
ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging.
2015 Feb;42(2):210-4. doi: 10.1007/s00259-014-2915-3. Epub 2014 Sep 24. PubMed
PMID: 25248644.


400: Tolmachev V, Malmberg J, Estrada S, Eriksson O, Orlova A. Development of a
124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET 
staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
Int J Oncol. 2014 Jun;44(6):1998-2008. doi: 10.3892/ijo.2014.2376. Epub 2014 Apr 
10. PubMed PMID: 24718894.


401: Maurer T, Eiber M, Krause BJ. [Molecular multimodal hybrid imaging in
prostate and bladder cancer]. Urologe A. 2014 Apr;53(4):469-83. doi:
10.1007/s00120-014-3440-5. Review. German. PubMed PMID: 24700188.


402: Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B,
Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first 
therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting
PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014
Jul;41(7):1280-92. doi: 10.1007/s00259-014-2713-y. Epub 2014 Feb 28. PubMed PMID:
24577951; PubMed Central PMCID: PMC4052014.


403: Lesche R, Kettschau G, Gromov AV, Böhnke N, Borkowski S, Mönning U,
Hegele-Hartung C, Döhr O, Dinkelborg LM, Graham K. Preclinical evaluation of BAY 
1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen
for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014
Jan;41(1):89-101. doi: 10.1007/s00259-013-2527-3. Epub 2013 Aug 17. PubMed PMID: 
23955632.


404: Röthke MC, Afshar-Oromieh A, Schlemmer HP. [Potential of PET/MRI for
diagnosis of prostate cancer]. Radiologe. 2013 Aug;53(8):676-81. doi:
10.1007/s00117-013-2499-0. German. PubMed PMID: 23949436.


405: Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on
prostate-specific membrane antigen. Curr Top Med Chem. 2013;13(8):951-62. Review.
PubMed PMID: 23590171; PubMed Central PMCID: PMC4067736.


406: Graham K, Lesche R, Gromov AV, Böhnke N, Schäfer M, Hassfeld J, Dinkelborg
L, Kettschau G. Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic
acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging
of prostate cancer. J Med Chem. 2012 Nov 26;55(22):9510-20. doi:
10.1021/jm300710j. Epub 2012 Oct 24. PubMed PMID: 23025786.


407: Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P.
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med. 2011
Jan;41(1):29-44. doi: 10.1053/j.semnuclmed.2010.08.005. Review. PubMed PMID:
21111858; PubMed Central PMCID: PMC3392994.


408: Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K,
VanBrocklin HF, Berkman CE, Jones EF. Assessment of an 18F-labeled
phosphoramidate peptidomimetic as a new prostate-specific membrane
antigen-targeted imaging agent for prostate cancer. J Nucl Med. 2009
Dec;50(12):2042-8. doi: 10.2967/jnumed.109.066589. Epub 2009 Nov 12. PubMed PMID:
19910433; PubMed Central PMCID: PMC3575752.


409: Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed
tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol. 2009
Sep;21(5):469-74. doi: 10.1097/CCO.0b013e32832d56e4. Review. PubMed PMID:
19535981; PubMed Central PMCID: PMC2788311.


410: Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of
prostate cancer. Methods. 2009 Jun;48(2):193-9. doi: 10.1016/j.ymeth.2009.03.021.
Epub 2009 Apr 9. Review. PubMed PMID: 19362147.


411: Larson SM, Schöder H. Advances in positron emission tomography applications 
for urologic cancers. Curr Opin Urol. 2008 Jan;18(1):65-70. Review. PubMed PMID: 
18090493.


412: Sodee DB, Sodee AE, Bakale G. Synergistic value of single-photon emission
computed tomography/computed tomography fusion to radioimmunoscintigraphic
imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28. PubMed PMID:
17161036.


413: Hasegawa BH, Wong KH, Iwata K, Barber WC, Hwang AB, Sakdinawat AE, Ramaswamy
M, Price DC, Hawkins RA. Dual-modality imaging of cancer with SPECT/CT. Technol
Cancer Res Treat. 2002 Dec;1(6):449-58. PubMed PMID: 12625772.